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Abstract
The development of science and technology has enabled the use of more covari-
ates. As a result, it has become more difficult to identify dependencies among many
covariates. Dimension reduction provides an efficient way to handle this issue by sum-
marizing the effect of covariates via a few linear combinations of covariates. In this
dissertation, two methodologies for real-life problems are provided by using dimension
reduction equipped with semiparametric theory. The use of semiparametrics allows
maximal flexibility of the model by letting some features of the model completely
unspecified, while we still enjoy the interpretability of the model through estimating
the parameters of interest. The last two chapters in this work present contributions to
classification and pathway activity estimation: (1) we propose an optimal semipara-
metric linear classifier for two groups and show that the estimator outperforms any
other linear classifiers; (2) we offer a two-stage analysis for high-dimensional breast
cancer survival data through combining a factor model and the general index model
for survival data.
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Chapter 1
Introduction
This work focuses mainly on the adaptation of dimension reduction and semipara-
metric treatment for complicated real data problems. Dimension reduction enables
us to reduce a high dimension of data to moderate size by possibly discovering smaller
linear combinations of covariates. Semiparametrics make use of geometric tools to
construct the space of influence functions, which have their unique estimators (Bickel
et al., 1993; Tsiatis, 2006). By dealing with the influence functions structure, we can
avoid estimating the nuisance parameter in typical semiparametric models. Allowing
the space of parameters in a semiparametric model to be infinite dimensional, we are
able to enjoy a maximal flexibility of statistical models that we assume for the data.
Below we provide a brief review of dimension reduction and semiparametric methods.
1.1 Overview of Dimension Reduction
Massive data and its high dimensionality have become major characteristics of
scientific data over the past several decades. There are two well-known approaches in
order to reduce high dimensionality: variable selection and dimension reduction. The
underlying rationale of variable selection is that a subset of variables is significant
to explain the response variable; in other words, unselected variables are considered
as redundant variables. On the other hand, dimension reduction can consider all
dependencies among covariates in terms of a few linear combinations of covariates.
In this work, we deal with the dimension reduction technique, whereas we do not
investigate variable selection.
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We let Y ∈ R be the response variable, and X be a p-dimensional random vector,
X = (X1, . . . , Xp) ∈ Rp. Let us suppose that there is a p× d matrix β such that
pr(Y ≤ y|x) = pr(Y ≤ y|βTx), (1.1)
for all y ∈ R. It implies that the accountability of x on Y can be exactly the same as
the one of βTx whose dimensionality is d, which is possibly much less than p. Since
β is not identifiable, the goal of dimension reduction is to find the central subspace
SY |x, which is the subspace spanned by column vectors of β (Cook, 1998).
Unlike (1.1), we may be interested in the mean of Y conditional on x, E(Y |x).
In this scenario, we have a weaker assumption as follows:
E(Y |x) = E(Y |βTx), (1.2)
where β is a p×d matrix with d p, which is also not identifiable. (1.2) is called the
central mean subspace problem whose goal is to identify the central mean subspace
SE(Y |x), which is the space spanned by the columns of β satisfying (1.2).
The estimation of the central subspace or the central mean subspace is a major
part in dimension reduction. The methodologies for the estimation are broken into
three categories based on dimension reduction literature: (1) inverse regression based
methods, (2) non-parametric methods, and (3) semiparametric methods. More de-
tailed review for these estimation approaches as well as determination of the structural
dimension d are well organized in Ma and Zhu (2013).
1.2 Overview of Semiparametrics
We consider a class of regular and asymptotically linear estimators satisfying
√
n(β̂ − β) = 1√
n
n∑
i=1
ϕi + op(1), (1.3)
where ϕi is referred to as the influence function of the i-th observation, which is i.i.d.
random vector, and E(ϕ) = 0 and E(ϕϕT) is bounded and nonsingular matrix.
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The concept of an influence function was first introduced by Hampel (1968), which
provides the influence of an observation (Hampel, 1974). From (1.3), we notice that
the variance of an influence function is the asymptotic variance of an RAL estimator,
β̂. In other words, the efficiency of estimators can be compared in terms of the
variance of their influence functions. Therefore, seeking an estimator whose variability
is the smallest among a class of RAL estimators is equivalent to searching for an
influence function whose variance is the smallest among all influence functions. To
this end, we make use of the geometry of influence function in the Hilbert space. In
summary, it is a process to find an influence function that has the smallest distance
to the origin in the Hilbert space. For more details, see Section 2.2 of Chapter 2, or
Bickel et al. (1993), or Tsiatis (2006).
This dissertation is organized as follows. In Chapter 2, we propose an optimal
linear classifier, which achieves the semiparametric efficiency bound. It implies that
there is no hope to find out an linear estimator that has a smaller variance than
ours. In Chapter 3, we provide a two-stage analysis technique to analyze the relation
between the survival time of patients with breast cancer tumor and their pathway
activity levels that are estimated from gene expressions. There are many areas to
be extended since the methodologies we adapt can be applied to any type of high-
dimensional data.
3
Chapter 2
An Optimal Semiparametric Method for
Two-Group Classification 1
Summary: In the classical discriminant analysis, when two multivariate normal dis-
tributions with equal variance-covariance matrices are assumed for two groups, the
classical linear discriminant function is optimal with respect to maximizing the stan-
dardized difference between the means of two groups. However, for a typical case-
control study, the distributional assumption for the case group often needs to be
relaxed in practice. Komori et al. (2015) proposed the generalized t-statistic to ob-
tain a linear discriminant function which allows for heterogeneity of case group. Their
procedure has an optimality property in the class of consideration. We perform a fur-
ther study of the problem and show that additional improvement is achievable. The
approach we propose does not require a parametric distributional assumption on the
case group. We further show that the new estimator is efficient, in that no further
improvement is possible to construct the linear discriminant function more efficiently.
We conduct simulation studies and real data examples to illustrate the finite sample
performance and the gain that it produces in comparison with existing methods.
1Baek, S., Komori, O., and Ma, Y. (2018). An Optimal Semiparametric Method for Two-Group
Classification, Scandinavian Journal of Statistics, in press. Reprinted here with permission of the
Wiley.
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2.1 Introduction
Classification has a wide range of applications in many different fields such as
medical studies and pattern recognition, as well as in practical subjects in statistics.
The simplest classification problem is a two group one, where the issue often reduces
to finding a suitable quantity that enables one to classify an observation into either a
“case” or a “non-case” (“control”) based on the observation’s p-dimensional covariate,
X ∈ Rp. The earliest literature in classification assumes that X has normal distribu-
tion in both groups with equal variance, say Ip, but unequal mean. In this case, the
optimal linear discriminant function is well known to be βTx, where β = µ/(µTµ)1/2
and µ = E(X | Y = 1)− E(X | Y = 0) (Mardia et al., 1980).
However, the equal variance assumption can be stringent. For example, heteroge-
nious variance between case group and control group is common in the medical stud-
ies, particularly for differential gene expression detection in microarray data analysis:
see Tibshirani and Hastie (2007) and Lian (2008) for typical examples. Likewise,
normality assumption for both groups can also be violated. For example, in practice,
sufficient knowledge may be available for the control group so that suitable transfor-
mation may be applied to X to arrive at a standard normal distribution assumption
for the control group. However, it may be unclear what kind of distribution the case
group has under the same transformation.
Based on these considerations, Komori et al. (2015) relaxed the assumption on
the distribution on X in the case group. They assume the control group covariate
has standard normal distribution, i.e. X | Y = 0 ∼ N (0, Ip), and leave the case
group covariate distribution to be nonparametric. Under this more flexible setting,
µ simplifies to E(X | Y = 1), and they devise estimators for the linear discrimi-
nant parameter β = µ/(µTµ)1/2 tailored to the relaxed assumption on the covariate
distribution in the case group.
Specifically, Komori et al. (2015) consider a collection of n subjects that are either
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controls (Y = 0) or cases (Y = 1). In addition, each subject has available a p-
dimensional covariate X. They assume that the distribution X in the control group
is a multivariate normal with zero mean (0) and identity covariance (Ip), whereas the
distribution of X in the case group is unspecified. In addition, they further assume
that the covariates in the case group satisfies a linearity condition and a constant
variance condition, i.e. E(X | βTX, Y = 1) = ββTX and var(X | βTX, Y = 1) =
Ip − ββT. Under these assumptions, Komori et al. (2015) proposed a novel way
to estimate β, which improves upon the classical sample average estimator in that
it is consistent and it has smaller estimation variability. The estimator of Komori
et al. (2015) is based on a generalized t-statistic consideration, and it is shown to be
optimal within the class of the generalized t-statistic based estimators in that it has
the smallest variability.
The purpose of this paper is to reexamine the estimation of β under the same
setting of Komori et al. (2015) and to further improve the procedure. Using a com-
pletely different approach via semiparametrics (Bickel et al., 1993; Tsiatis, 2006), we
derive the optimal estimator of β among all the possible consistent estimators, which
are not only restricted to the t-statistic form. We show that our estimator attains
the semiparametric efficiency bound and provide further improvement over that of
Komori et al. (2015). In addition, numerical studies of our estimator demonstrate cer-
tain robustness property of our semiparametric efficient estimator, in that even when
only the linearity condition is satisfied, the estimator continues to perform well.
The rest of this paper is organized as follows. In Section 2.2, we briefly describe
the background for seimiparametric efficient estimator, and devise three estimators
under three circumstances of the covariate distributions. We compare with the esti-
mator by Komori et al. (2015) in each case to gain understanding of both estimators.
Theoretical properties of the final proposed estimator is established in Section 2.3.
We perform numerical studies to illustrate the superiority of the new estimator, via
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both some simulations in Section 3.3 and empirical data in Section 3.4. We conclude
this paper with a short discussion in Section 2.6. Technical details are relegated to
an Appendix.
2.2 Semiparametric estimator
Model
Following the development in Komori et al. (2015), we consider the independent
and identically distributed (iid) samples (Xi, Yi), i = 1, . . . , n, where Yi = 0 or 1 and
Xi ∈ Rp. The joint probability density function (pdf) is
f(x, y) = {q0(2pi)−p/2 exp(−xTx/2)}1−y{(1− q0)θ(x)}y, (2.1)
where q0 = pr(Y = 0). We want to estimate
β ≡ µ
(µTµ)1/2
, (2.2)
where µ =
∫ xθ(x)dx, and θ(·) is the probability density function of X conditional on
Y = 1. Thus, the parameter of the interest is β(θ), where θ is infinite dimensional.
Without loss of generality, we assume the first component of µ to be positive, i.e.
µ1 > 0, since we can always perform rotation of the covariate components to ensure
µ1 6= 0 and can also consider −X as covariates to further ensure µ1 > 0.
Preliminaries for semiparametric estimator
The model in (2.1) is a semiparametric model, and we consider a class of regular
and asymptotically linear (RAL) estimators for the parameter β, where the estimator
β̂ satisfies
√
n(β̂ − β) = 1√
n
n∑
i=1
ϕi + op(1),
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which satisfies
√
n(β̂ − β)→ N
{
0, E(ϕϕT)
}
(2.3)
in distribution. Here E(ϕ) = 0 and E(ϕϕT) is bounded and nonsingular, and then
ϕi is referred to as the influence function of the i-th observation.
We consider the Hilbert space H of all p-dimensional measurable functions of
the observed data, h, with mean-zero and finite variance and the inner product is
defined as 〈h1,h2〉 = E(hT1 h2). The asymptotic variance of an RAL estimator is the
covariance of its influence function due to (2.3), and we seek an estimator with the
smallest asymptotic variance. Noting that the distance square of an element from the
origin in the Hilbert space is the trace of its variance, this process amounts to finding
out the element in the space of influence functions that has the smallest distance. For
more details, see Chapter 3 of Tsiatis (2006). Based on the semiparametric theory,
for example in Bickel et al. (1993), influence functions of RAL estimators are in
the linear space orthogonal to the nuisance tangent space, which is depicted below.
From the semiparametric perspective, our aim is to construct subspace of influence
functions, i.e., the nuisance tangent space orthogonal complement, and look for an
efficient influence function in the subspace.
To this end, we denote Λ the nuisance tangent space spanned by the score function
with respect to the nuisance parameter and Λ⊥ to be orthogonal complement to
Λ. According to the semiparametic theory, we construct the efficient score Seff by
projecting the score function with respect to the parameter of our interest β, i.e., Sβ,
to Λ⊥. Then the corresponding efficient influence can be represented as
ϕeff = {E(SeffSTeff)}−1Seff.
Hence, it subsequently leads to
√
n(β̂eff − β)→ N
{
0, E(ϕeffϕTeff)
}
,
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in distribution, where β̂eff is the efficient estimator. It means that for any influence
function ϕ 6= ϕeff, var(ϕ − ϕeff) is positive definite. More detailed procedure is
available in Chapter 4 of Tsiatis (2006).
To gain better understanding of the estimator in Komori et al. (2015) and the
classical estimator of β based on sample mean, we consider three different scenarios:
θ(x) is an arbitrary pdf, θ(x) satisfies the linearity condition alone, and θ(x) satisfies
both the linearity and the constant variance conditions. For each scenario, we derive
an efficient estimator and make comparisons with existing estimation results.
No restriction
We first consider the model described in (2.1) without any additional restrictions
on θ(x) other than θ(x) being a valid pdf of the random covariate X. We derive the
efficient estimator for β under this situation.
Let T be the tangent space which is a space spanned by the score vector. In
Appendix A.1, we derive the tangent space T and its orthogonal complement T ⊥ as
T = [Y a(X) : E{a(X) | Y = 1} = 0],
T ⊥ = [(1− Y )b(X)− Y {(1− q0)−1q0(2pi)−p/2
∫
b(x) exp(−xTx/2)dx} : ∀b(X)].
Note that µ = E(X|Y = 1). Obviously, we have n−1∑xiyi = (1 − q0)µ + op(1)
and n−1∑ni=1 yi = 1−q0 +op(1). Therefore, µ̂ ≡ ∑xiyi/∑ yi is a consistent estimator
for µ, i.e. µ̂ = µ+ op(1). We therefore easily obtain
β̂ = µ̂
(µ̂Tµ̂)1/2
=
∑xiyi∑
yi

(∑xiyi∑
yi
)T∑xiyi∑
yi

−1/2
= µ(µTµ)1/2 + op(1) = β + op(1).
This indicates that β̂ is an RAL estimator. We further derive the influence function
in Appendix A.2 and obtain the influence function for β̂ as
ϕ1(X, Y ) = YBX,
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where
B ≡ I− µ(µ
Tµ)−1µT
(1− q0)(µTµ)1/2 .
We now show that the influence function ϕ1(X, Y ) belongs to T , hence it is in
fact the efficient influence function. To see this, all we need to do is to verify that∫ Bxθ(x)dx = 0. This is certainly true because ∫ Bxθ(x)dx = B ∫ xθ(x)dx = Bµ =
0. The above result indicates that β̂ defined above is the efficient estimator for β
under the current model setting.
Note that this is also the classical estimator of β under normality and equal
variance assumptions for both control group and case group. Thus, an interesting
discovery here is that the classical estimator developed under the stronger conditions
is still valid under this much weaker condition and is even efficient.
Under linearity condition
We now consider model (2.1), with an additional assumption on θ(x). Specifically,
in addition to being a valid pdf, we further assume θ(x) satisfies
E(X | βTx, Y = 1) = ββTx. (2.4)
The property described in (2.4) is commonly referred to as the linearity condition.
It covers a wide range of distributions including all elliptical distributions (Eaton,
1983), hence is a reasonable assumption to make in many situations.
Differently from Section 2.2, we write our model explicitly in terms of β. Let
the marginal pdf of βTX be θ1(βTX), and the conditional pdf of X on βTX be
θ2(X,βTX). Then we have
f(x, y) = {q0(2pi)−p/2 exp(−xTx/2)}1−y{(1− q0)θ1(βTx)θ2(x,βTx)}y,
where θ1(βTx) is a pdf, while θ2(x,βTx) is a conditional pdf that satisfies∫
βTx fixed xθ2(x,β
Tx)dx = ββTx. We then proceed to derive the nuisance tangent
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space Λ and its orthogonal complement Λ⊥ in Appendix A.3. These are
Λ = [Y a(X,βTX) : E{a(X,βTX) | Y = 1} = 0,
E{(X− ββTX)aT(X,βTx) | βTx, Y = 1} = 0],
Λ⊥ = [(1− Y )b0(X) + Y {B1(βTx)(x− ββTx)− q0/(1− q0)(2pi)−p/2
∫
b0(x)
× exp(−xTx/2)dx} : ∀b0(X),B1(βTx)].
The score vector in this case is
Sβ = Y
{
θ′1(βTX)
θ1(βTX)
+ θ
′
2(X,βTX)
θ2(X,βTX)
}
X,
where the derivative on θ1, θ2 is with respect to βTX. To calculate the efficient score,
we project Sβ onto Λ⊥. To this end, define
U1 = X− ββTX,
U∗3 =
{
θ′1(βTX)
θ1(βTX)
+ θ
′
2(X,βTX)
θ2(X,βTX)
}
X,
B1(βTX) = E(U∗3UT1 | βTX, Y = 1){E(U1UT1 | βTX, Y = 1)}−
U3 = U∗3 −B1(βTX)U1,
then E(U1 | βTX, Y = 1) = 0, E(U3 | Y = 1) = 0, and E(U1UT3 | βTX, Y = 1) = 0.
Here and throughout the text, we use A− to denote the generalized inverse of a
symmetric matrix A. Specifically, let A = PΛPT be the singular value decom-
position, where Λ is invertible, then A− ≡ PΛ−1PT. It is easy to verify that
YB1(βTX)U1 ∈ Λ⊥, YU3 ∈ Λ, and Sβ = YB1(βTX)U1 + YU3. Thus
Seff = YB1(βTX)U1,
and the efficient influence function is
ϕ2(X, Y ) = (E[Y {B1(βTX)U1}⊗2])−YB1(βTX)U1,
where throughout the text, A⊗2 ≡ AAT for any matrix or vector A, and the optimal
estimation variance of β̂ is given by
V2,opt = (E[Y {B1(βTX)U1}⊗2])−. (2.5)
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To compare the optimal estimation variance given in (2.5) with the results pro-
vided in Komori et al. (2015), we further adopt their assumption that var(X |
βTX, Y = 1) = Q, hence E(XXT | βTX, Y = 1) = Q + (ββTX)⊗2, where
Q = Ip − ββT. Noting that following Appendix A.4, (2.5) can be represented as
V2,opt = {(1− q0)κ}−1Q−,
where κ = E[{θ′1(βTX)/θ1(βTX)}2 | Y = 1]. Let m1 = E(βTX | Y = 1), σ21 =
var(βTX | Y = 1), and σ2 = var(βTX) = q0 + (1 − q0)σ21 + q0(1 − q0)m21. The
asymptotic variance in Komori et al. (2015), denoted as Σ, is given as
Σ = {(1− q0)c}−1Q−,
where c = κ+ q0/(1− q0)− 1/{(1− q0)σ2}. Thus, to compare V2,opt and Σ, we only
need to compare κ and c. Note that (1− q0)c− (1− q0)κ = q0− 1/σ2. Thus, we find
that 
V2,opt < Σ, if q0 < 1σ2
V2,opt = Σ, if q0 = 1σ2
V2,opt > Σ, if q0 > 1σ2 .
In other words, there is no definitive relation between the efficient estimator derived
solely under the linearity condition and the estimator prescribed by Komori et al.
(2015), even though the latter estimator is constructed under stronger assumptions.
Under linearity and constant variance conditions
We now consider the identical model setting for θ(x) as in Komori et al. (2015)
and assume that both the linearity condition and the constant variance condition
hold, i.e. E(X | βTx, Y = 1) = ββTx and var(X | βTx, Y = 1) = Q. The constant
variance condition means that the variance of the regression error, after regressing
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X on βTX, is homoscedastic. This condition can be viewed as an extension of the
homoscedastic error assumption from univariate to multivariate response case. It is
satisfied when X is normally distributed, for example, hence often is not too stringent
in practice.
To facilitate the theoretical development, we perform a reparameterization. Specif-
ically, instead of directly estimating β in (2.2), we investigate the estimation of
α ≡ µ/µ1, where µ = ∫ xθ(x)dx and µ1 is the first component of µ and is as-
sumed to be nonzero. Note that the mapping between β and α is one-to-one, in that
β = α/‖α‖ and α = β/β1, hence estimation and inference regarding β is equivalent
to that regarding α. The reason we choose to work with α, or in fact, the subvector
of α formed by the second to the p-th component of α, denoted αL, is that αL is
not subject to any constraints and hence the semiparametric analysis can be directly
applied without any modification. Under the new parameterization, the linearity and
constant variance conditions take the form
E(X | αTx, Y = 1) = (αTα)−1ααTx (2.6)
and
var(X | αTx, Y = 1) = Q = I− (αTα)−1ααT. (2.7)
These conditions further lead to E(XXT | αTX, Y = 1) = Q+ (αTα)−2(ααTX)⊗2.
As in Section 2.2, we write the pdf of (X, Y ) as
f(x, y) = {q0(2pi)−p/2 exp(−xTx/2)}1−y{(1− q0)θ1(αTx)θ2(x,αTx)}y,
where θ1(αTx) is the marginal pdf of αTX, while θ2(x,αTx) is the pdf of X condi-
tional onαTX and it satisfies ∫ xθ2(x,αTx)dx = (αTα)−1ααTx and ∫ xxTθ2(x,αTx)
dx = Q+(αTα)−2(ααTx)⊗2. The nuisance tangent space Λ and its orthogonal com-
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plement space are derived in Appendix A.5 and they have the form
Λ = (Y a(X,αTX) : E{a(X,αTX) | Y = 1} = 0,
E[{X− (αTα)−1ααTX}aT(X,αTx) | αTx, Y = 1] = 0,
E[vec{XXT −Q− (αTα)−2(ααTX)⊗2}aT(X,αTx) | αTx, Y = 1] = 0,
a ∈ Rp−1),
Λ⊥ =
(
(1− Y )b0(X) + Y [B1(αTx){x− (αTα)−1ααTx}
+B2(αTx)vec{xxT −Q− (αTα)−2(ααTx)⊗2}
−q0/(1− q0)(2pi)−p/2
∫
b0(x) exp(−xTx/2)dx] :
∀b0(X) ∈ Rp−1,B1(αTx) ∈ R(p−1)×p,B2(αTx) ∈ R(p−1)×p2
)
.
We now calculate the score vector. Identical to Section 2.2, the score vector is
Sα = Y
{
θ′1(αTX)
θ1(αTX)
+ θ
′
2(X,αTX)
θ2(X,αTX)
}
XL,
where XL is the vector X without the first component. To further derive the efficient
score, we project Sα to Λ and Λ⊥. To this end, let αL be the α vector without the
first component 1, and QLL be the Q matrix without the first row and first column,
where
Q =
( Q11 Q12
Q21 QLL
)
.
Here QLL is the variance-covariance matrix of XL conditional on αTX, which is the
same as conditional on X1, hence is invertible in general. Define
U1 = XL − (0, Ip−1)(αTα)−1ααTX = (0, Ip−1)QX
U∗2 = vec[(0, Ip−1){XXT −Q− (αTα)−2(ααTX)⊗2}(0, Ip−1)T]
U2 = U∗2 − E(U∗2UT1 | αTX, Y = 1){E(U1UT1 | αTX, Y = 1)}−1U1
U∗3 =
{
θ′1(αTX)
θ1(αTX)
+ θ
′
2(X,αTX)
θ2(X,αTX)
}
XL,
B1(αTX) = E(U∗3UT1 | αTX, Y = 1){E(U1UT1 | αTX, Y = 1)}−1.
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We can see that E(U2UT2 | αTX, Y = 1) is the variance of U2, which concerns the
fourth moment of XL conditional on αTX, or equivalently, conditional on X1, hence
is also invertible in general. Thus, we further define
B2(αTX) = E(U∗3UT2 | αTX, Y = 1){E(U2UT2 | αTX, Y = 1)}−1
U3 = U∗3 −B1(αTX)U1 −B2(αTX)U2,
then E(U1 | αTX, Y = 1) = 0, E(U2 | αTX, Y = 1) = 0, E(U3 | Y = 1) =
0, E(U1UT2 | αTX, Y = 1) = 0, E(U1UT3 | αTX, Y = 1) = 0, and E(U2UT3 |
αTX, Y = 1) = 0.
It is easy to verify that Y {B1(αTX)U1 + B2(αTX)U2} ∈ Λ⊥, YU3 ∈ Λ, and
Sα = Y {B1(αTX)U1 +B2(αTX)U2}+ YU3. Thus
Seff = Y {B1(αTX)U1 +B2(αTX)U2},
and the efficient influence function is
ϕ3(X, Y,αL) = (E[Y {B1(αTX)U1 +B2(αTX)U2}⊗2])−1
×Y {B1(αTX)U1 +B2(αTX)U2}, (2.8)
and the optimal variance of the αL estimation is given by
Vα,opt = (E[Y {B1(αTX)U1 +B2(αTX)U2}⊗2])−1. (2.9)
2.3 Efficiency of semiparametric estimator
In this section, we show that the estimator proposed by Komori et al. (2015) is not
efficient among all the possible consistent estimators of αL, while we can construct the
efficient estimator by solving the estimating equation ∑ni=1ϕ3(X, Y,α) = 0, where
ϕ3(X, Y,α) is defined in (2.8). We denote this estimator β̂.
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To describe the estimator of Komori et al. (2015) in detail, we first define some
notations. Let n0 =
∑n
i=1(1− Yi) and n1 =
∑n
i=1 Yi. Let
x¯ = 1
n0
n∑
j=1
xjI(Yj = 0),
S = 1
n0 − 1
n∑
j=1
(xj − x¯)(xj − x¯)TI(Yj = 0),
U(βTx) = logθ˜1(βTx)− logφ(βTx,m, σ2),
θ˜1(βTx) : pdf of βTx given Y = 1,
φ(βTx,m, σ2) : normal pdf with mean m and variance σ2,
LU(β) =
1
n1
n∑
j=1
U
{
βT(xj − x¯)
(βTSβ)1/2
}
I(Yj = 1).
Komori et al. (2015) proposed the generalized t-statistic estimate β̂K as
β̂K = argmax
β
LU(β).
In Appendix A.6, we derived the influence function of Komori et al. (2015)
ϕK(Xi, Yi) =
1
β1k
Q−1LL(0, Ip−1)ϕ(Xi, Yi) (2.10)
= − 1(1− q0)β1kQ
−1
LL(0, Ip−1){U ′(βTxi)QxiI(Yi = 1) +RiI(Yi = 0)},
where Ri = [E{I(Yj = 1)U ′′(βTXj)βXTj }q−10 Qxi−E{I(Yj = 1)U ′(βTXj)}q−10 Qxi−
(1/2)E{I(Yj = 1)U ′′(βTXj)βTXjβXTj }q−10 Q(xixTi − Ip)β − (1/2)E{I(Yj = 1)×
U ′(βTXj)(βXTj + 2βTXjIp − 3βTXjββT)}q−10 (xixTi − Ip)β]I(Yi = 0). In Appendix
A.7, we further develop Proposition 2.1.
Proposition 2.1. ϕK(X, Y ) is a valid influence function.
Semiparametric theory dictates that a valid influence function can always be de-
composed as the sum of the efficient influence function and an additional component
belonging to Λ⊥. For an arbitrary influence function ϕ, ϕ = ϕeff+ϕ∗, where ϕ∗ ∈ Λ⊥,
always holds. Using this property directly, we prove in Appendix A.8 the following
proposition.
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Proposition 2.2. β̂ is an efficient estimator, whereas β̂K is not efficient.
A direct consequence of the efficiency of β̂ is the resulting optimality of the area
under the receiver operating characteristic curve (AUC). AUC is commonly used to
quantify the performances of classifiers (Su and Liu, 1993). A large AUC implies that
a classifier discriminates well between two groups. In Corollary 2.1, we show that our
proposed estimator β̂ attains the largest possible AUC among all possible classifiers.
The proof of the following corollary is provided in Appendix A.9.
Corollary 2.1. Under the linearity and the constant variance conditions stated in
(2.6) and (2.7), β̂ is optimal in terms of AUC, which implies that on average when
sample size goes to infinity, it yields the largest AUC.
2.4 Simulations
In this section we carry out simulations to evaluate the finite sample performance
of various estimators established in Sections 2.2, 2.2 and 2.2. For convenience we de-
note “Method I” the classical estimator under no assumption in Section 2.2, “Method
II” the semiparametric estimator developed under the linearity condition (2.4) in Sec-
tion 2.2, and “Method III” the semiparametric estimator established under both the
linearity and the constant variance conditions (2.6) and (2.7), in Section 2.2. We
name the estimator provided by Komori et al. (2015) as “Method IV”. For further
comparison suggested by a referee, we add the Fisher linear discriminant method,
named as “Method V”. In order to make a clear comparison of the five different
estimators, we use the same simulation setting as that in Komori et al. (2015).
In all the simulations, we generated 1000 datasets of sample size n = 200, where
each Yi is generated from a Bernoulli distribution where the probability Yi = 0 is q0,
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and subsequently a p = 10 dimensional Xi is generated from
X | Y = 0 ∼ N (0, Ip),
X | Y = 1 ∼ (1− 1 − 2) N (µ1,V1) + 1 N (µ2,V2) + 2 N (µ3,V3),
where 1 = 2 = 0.1, µ1 = (−1,−0.1, · · · ,−0.1)T. The difference between the three
simulation settings is the following. In Simulation 1, we set µ2 = (1, 0.1, · · · , 0.1)T,
µ3 = (3, 0.3, · · · , 0.3)T, V1 = V2 = V3 = Ip, and q0 = 0.5. It is easy to verify
that in Simulation 1, both the linearity and the constant variance conditions are
satisfied. In Simulation 2, we let µ2 = (1, 0.1, · · · , 0.1)T, µ3 = (3, 0.3, · · · , 0.3)T,
V1 = Ip, V2 = 2Ip, V3 = (1/2)Ip, and q0 = 0.8. Thus, only the linearity condition is
satisfied in Simulation 2, while the constant variance condition is violated. Finally,
in Simulation 3, we set µ2 = (1, 0.1, 0.2, · · · , 0.9)T, µ3 = (3, 0.3, 0.4, · · · , 0.11)T,
V1 = V2 = V3 = Tp, and q0 = 0.5, where Tp is a Toeplitz matrix with the element
tij = 1/(|i− j|+ 1)2, i, j = 1, · · · , p. In Simulation 3, neither the linearity condition
nor the constant variance condition is satisfied.
We experimented all five methods in all three simulations. In implementing our
proposed semiparametric estimators in Method II and Method III, we replaced the
expectations such as E(· | βTX, Y = 1) and E(· | αTX, Y = 1) with their corre-
sponding kernel based nonparametric estimation.
We provide the absolute biases and sample standard deviations of each estimator
in Simulations 1, 2 and 3 in Tables 3.1, 3.2 and 2.3 respectively. Further, in Figure
2.1 and Figure 2.2, we compared the performance of the five estimators in terms of
their mean squared errors (MSE), calculated using the average of ‖β̂−β‖2, and AUC,
over 1000 simulations. The boxplots of the estimated individual component in β̂ are
given Figure 2.3, 2.4 and 2.5.
We first examine the results in Simulation 1. Because all the estimators are
consistent in this setting, we expect to see very small bias for all estimators. This is
indeed the case in most cases based on the bias results in Table 3.1 and the boxplot
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in Figure 2.3, except the β1 estimation for Method I, II and V. We experimented to
increase the sample size, and see that the corresponding biases decreases as sample size
increases, indicating that this is a finite sample size phenomenon. Further, it is clear
that Method III has the smallest estimation variability, reflected in the very narrow
boxes in Figure 2.3 and smallest “std” values in Table 3.1. The superior performance
of Method III is within our expectation because it is the optimal estimator in this case.
What surprises us is the overall performance of Method II. This estimator only takes
into account the linearity condition, however it largely performs better than Method
IV, which is designed to make use of both the linearity and the constant variance
conditions. In summary, the superiority of Method III is evident in Simulation 1 in
terms of both MSE and AUC measures.
We next inspect the results in Simulation 2, where only the linearity condition
is satisfied. Although in theory only Methods I and II are consistent while Methods
III, IV and V are inconsistent, we observe that all five methods show very small
bias for most components in β. The finite sample estimation bias is shown in β1,
which is again decreasing when we further increase the sample size. Comparing the
amount of bias and variance, much to our surprise, Method III again shows the best
performance, whereas Methods II and IV have similar performances. This can be
further verified from the boxplots in Figure 2.1 and Figure 2.2.
Finally, in Simulation 3, where both linearity and constant variance conditions are
violated, only Method I is valid in theory. From Table 2.3 and Figure 2.5, we can see
that Method I indeed performs relatively well compared to other estimators. Much
to our relief, Method II and III also perform not very badly except in estimating β1,
where again we believe the sample size is likely causing some inferior performances.
In summary, the simulation results confirmed our expectation on the performance
of the five estimators. The messages are mainly the following. If both linearity
condition and constant variance conditions are satisfied, Method III is to be used to
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obtain both small bias and small variability. Moreover, Method III shows the best
performance in that it has largest values of AUC among all methods. If only linearity
condition is satisfied, Method II or III can be applied to obtain the minimal MSE.
If none of the linearity condition and the constant variance condition is satisfied, we
should use Method I to safeguard us in obtaining a consistent estimator.
Following the request of a referee, we repeated the same simulations with sample
sizes n = 400 and n = 800. Please see the results for n = 400 in Tables 3.1-2.3 and
Figures 2.6-2.7. The results for n = 800 can be found from the online supplementary
material. Similar conclusions can be drawn.
2.5 Applications
In this section we analyze two datasets to illustrate further our semiparametric
proposals. For easier comparison of the five different methods, we first analyzed the
asthma dataset studied in Komori et al. (2015). This particular data set contains
measurements of allergen markers for asthmatic (Y = 1) and non-asthmatic (Y = 0)
individuals (Dottorini et al. 2011). We consider two biomarkers, D03 and X907, and
compare the performance of the five estimators.
We first transformed the data so that X¯ = 0 and S = I2 for the non-asthmatic
individuals. We then fitted the following Gaussian mixture model
X | Y = 0 ∼ N (0, I2),
X | Y = 1 ∼ (1− ̂1 − ̂2) N (0, I2) + ̂1 N (µ̂2, V̂2) + ̂2 N (µ̂3, V̂3),
where the parameters are estimated by the maximum likelihood estimators. This
yields ̂1 = 0.23, ̂2 = 0.30, µ̂2 = (1.79, 0)T, µ̂2 = (3.51, 0)T,
V̂2 =
 0.90 0
0 0.50
 , and V̂3 =
 0.07 0
0 0.82
 .
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We subsequently adopted parametric bootstrap to generate 1000 data sets from the
fitted model. Each bootstrap data set has the same sample size as the original data,
with n = 827, and q0 = 0.41. It is easily checked that the linearity condition holds,
while the constant variance condition is violated for this fitted model.
In Table 2.4, we provide the absolute bias and sample standard deviations for
each of the five estimation methods. In Figure 2.8 and Figure 2.9, we examine the
overall performance of the five estimators via their MSE and AUC. The sample mean
squared errors of five estimators are respectively 4.00e−4, 2.00e−4, 1.00e−4, 1.19e−3,
and 8.59e−3. Furthermore, the sample mean AUCs of five estimators are 0.740817,
0.740825, 0.740830, 0.740818, and 0.740496, respectively. Based on the results in both
the table and the plots, Method III appears to have the best performance among the
five estimators, in terms of bias, variability as well as AUC. We also should treat
the numerical performance with caution, since these values are based on finitely
many simulation repeats and hence have variabilities themselves, as pointed out by
a referee. While it is not a surprise that Method III has the smallest variability, it
is worth noting that it also has the smallest bias. In fact, since we are treating a
case where only linearity condition holds, Method III does not guarantee to produce
a consistent estimator and could be potentially very biased. However, the empirical
results of Method III contain the smallest bias among all estimators. The superior
performance we observe here is also reflected in Simulation 2, where Method III
shows certain robustness and yields very good performance even though the constant
variance condition is violated. On the other hand, Method II also perform very well
in general and is the second best performing estimator. This of course does not come
as a surprise since Method II is theoretically the most efficient estimator among all
consistent estimators in this case.
We also analyzed a breast cancer data set studied in Wang et al. (2005). This
data set contains 286 patients with lymph-node-negative breast cancer, among which
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107 experienced cancer relapse in five years (Y = 1) and 179 not (Y = 0). A total of
17819 genes are contained in the data set as covariates, while it is believed that the
number of informative genes is at most 76 (Wang et al., 2005). In fact, Wang et al.
(2005) reported an AUC of 0.694 using 76 covariates.
To investigate whether or not more efficient estimation procedures will enable us
to achieve better prediction using less number of covariates, we performed a careful
analysis through a ten-fold crossvalidation. Specifically, we first transformed all of
the covariates such that each covariate has mean zero and variance one. We then
randomly selected 90% of the observations to form a training sample and 10% a
testing sample. Using the training sample, following Cui et al. (2015), we proceed to
sort all the covariates according to their association with Y measured by
EXj [varY {F (Xj | Y )}]
for the jth covariate Xj, where F (Xj | Y ) is the cdf of the jth covariate conditional
on the response variable. We then selected p covariates with the largest estimated
association with Y , and estimated the corresponding β using the training data based
on the five different methods studied above, and evaluated their prediction perfor-
mance using the testing data via AUC. This procedure was repeated ten times and in
Table 2.5, we provide the average AUCs for the five methods when different number
of covariates p are included into the model. For comparison, AUCs for the Fisher
linear discriminant method, denoted as “Method V”, are also given (Fisher, 1936).
Based on the results in Table 2.5, we can see that as soon as p ≥ 20, the AUCs
obtained from any of three semiparametric methods are already better than the one
from Wang et al. (2005), which used 76 covariates. Further, once p ≥ 25, the per-
formance stabilizes, suggesting that further increasing p to include more covariates
may not be helpful in terms of prediction. Indeed, we find that the association of the
covariate and the response becomes very week (≤ 0.00055) when p passes 35. Hence,
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based on these observations, we did not further increase the number of covariates to
beyond 35.
For all different values of p between 5 and 35, the performance of methods I,
II and III are always better than Method IV of Komori et al. (2015) and Method
V of Fisher (1936), reflecting the importance of the efficient estimation. Further,
the performances of the methods I, II, III are very close, while Method I slightly
outperforms the other two methods for p ≥ 10. This indicates that likely the linearity
condition and the constant variance condition may both be violated for some covariate
combinations. Thus, we would consider Method I the most suitable method to use
to classify a patient in analyzing the breast cancer data.
As a referee pointed out, it would be important to assess whether or not the
linearity and constant variance conditions hold in the data analysis. Note that the
linearity and constant variance conditions need to be satisfied only at the true β.
Since we do not know the true β, we substitute it with the estimated β̂. We check if
the linearity condition is satisfied by inspecting the scatter plots of each component
of X against β̂Tx to see if they exhibit linear patterns. To further check the constant
variance condition, we inspect the relation between the product of the jth and kth
residual components against β̂Tx. If there is no clear pattern for all (j, k) combina-
tions, where j, k = 1, . . . , p, then the constant variance condition are likely to hold.
As an example, for the breast cancer data set, in Figure 2.10, we provide the scatter
plot for a component of X and β̂Tx in the left panel, and the product of two residual
components against β̂Tx in the right. For these plots, the fitted linear and constant
regression lines are imposed respectively. They suggest that both conditions may be
violated, in sense that the left plot seems not show an evident linear pattern visually,
while there is a clear pattern in the right plot showing heteroscedasticity.
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2.6 Discussion
We have derived efficient semiparametric estimators for the discriminant direction
β in two-group classification under three different scenarios. For a typical case-control
study, relaxing the assumption on distribution for case group can be practically more
useful compared to assuming multivariate normal with different mean and equal co-
variance. Under linearity and constant variance conditions, our estimator is superior
to the one provided by Komori et al. (2015) in several aspects. First, our estimator is
more efficient. Secondly, our estimator achieves the semiparametric efficiency. Lastly,
our numerical results suggest that our estimator (Method III) has certain robustness
property which gives good performance even under linearity condition only. While
the first two properties are backed up by our theoretical results, it is unclear to us
why the robustness properties are also possessed by the estimator. Understanding
this seemingly robustness property is worth further investigation.
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Table 2.1: Simulation 1. Comparisons of different methods I, II, III, IV, and V when linearity and constant variance conditions
are both satisfied. Absolute bias (bias) and sample standard deviation (std) are based on 1000 simulations with sample sizes
n = 200 and n = 400.
Method β1 β2 β3 β4 β5 β6 β7 β8 β9 β10
n = 200
true -0.9578 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957
I bias 0.1893 0.0121 0.0279 0.0140 0.0142 0.0330 0.0131 0.0187 0.0247 0.0161
std 0.1111 0.1974 0.1965 0.1966 0.1931 0.1950 0.1944 0.1967 0.1900 0.2003
II bias 0.1544 0.0057 0.0082 0.0075 0.0061 0.0050 0.0031 0.0062 0.0094 0.0088
std 0.4263 0.1031 0.0996 0.1063 0.1113 0.1133 0.1101 0.1046 0.1024 0.1043
III bias 0.0120 0.0022 0.0033 0.0023 0.0016 0.0006 0.0011 0.0020 0.0037 0.0013
std 0.0703 0.0452 0.0473 0.0505 0.0487 0.0394 0.0559 0.0503 0.0477 0.0519
IV bias 0.0211 0.0066 0.0058 0.0048 0.0054 0.0155 0.0002 0.0013 0.0108 0.0129
std 0.1834 0.1900 0.1806 0.1822 0.1872 0.1828 0.1786 0.1877 0.1876 0.1840
V bias 0.5048 0.0555 0.0485 0.0456 0.0432 0.0370 0.0347 0.0517 0.0400 0.0440
std 0.1865 0.3025 0.3011 0.3042 0.3080 0.3062 0.3098 0.3174 0.3069 0.3028
n = 400
true -0.9578 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957
I bias 0.1031 0.0136 0.0125 0.0100 0.0130 0.0116 0.0121 0.0132 0.0197 0.0071
std 0.0643 0.1544 0.1503 0.1515 0.1491 0.1547 0.1492 0.1516 0.1442 0.1465
II bias 0.1354 0.0045 0.0029 0.0052 0.0033 -0.0003 0.0036 0.0032 0.0070 0.0057
std 0.4202 0.0896 0.0836 0.0874 0.0839 0.0910 0.0898 0.0910 0.0927 0.0912
III bias 0.0079 -0.0007 0.0007 0.0009 0.0014 0.0003 0.0005 0.0012 -0.0008 -0.0005
std 0.0482 0.0374 0.0483 0.0361 0.0359 0.0359 0.0410 0.0325 0.0397 0.0366
IV bias -0.0019 -0.0081 -0.0029 0.0019 0.0055 -0.0045 -0.0008 -0.0018 0.0013 -0.0024
std 0.0628 0.1067 0.1057 0.1081 0.1066 0.1061 0.1080 0.1020 0.1054 0.1044
V bias 0.3895 0.0291 0.0334 0.0409 0.0360 0.0264 0.0235 0.0406 0.0282 0.0362
std 0.1573 0.2700 0.2800 0.2803 0.2653 0.2707 0.2713 0.2704 0.2738 0.2746
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Table 2.2: Simulation 2. Comparisons of different methods I, II, III, IV, and V when only linearity condition is satisfied.
Absolute bias (bias) and sample standard deviation (std) are based on 1000 simulations with sample sizes n = 200 and n = 400.
Method β1 β2 β3 β4 β5 β6 β7 β8 β9 β10
n = 200
true -0.9578 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957
I bias 0.3533 0.0416 0.0359 0.0296 0.0408 0.0391 0.0308 0.0511 0.0211 0.0482
std 0.1949 0.2626 0.2462 0.2520 0.2477 0.2507 0.2467 0.2533 0.2519 0.2454
II bias 0.2692 0.0101 0.0118 0.0185 0.0167 0.0330 0.0162 0.0274 0.0168 0.0115
std 0.4634 0.1733 0.1636 0.1734 0.1690 0.1628 0.1719 0.1684 0.1611 0.1758
III bias 0.0398 0.0255 0.0311 0.0317 0.0262 0.0300 0.0246 0.0242 0.0294 0.0335
std 0.0774 0.1063 0.1183 0.1125 0.1061 0.1086 0.1129 0.1113 0.1121 0.1090
IV bias 0.1687 0.0222 0.0229 0.0263 0.0057 0.0199 0.0139 0.0206 0.0164 0.0133
std 0.3235 0.2175 0.2163 0.2162 0.2026 0.2173 0.2070 0.2127 0.2132 0.2024
V bias 0.4812 0.0352 0.0317 0.0558 0.0254 0.0516 0.0340 0.0586 0.0602 0.0637
std 0.2131 0.3033 0.3025 0.3100 0.2972 0.2952 0.3018 0.2962 0.3033 0.2921
n = 400
true -0.9578 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957 -0.0957
I bias 0.2285 0.0367 0.0219 0.0244 0.0235 0.0366 0.0290 0.0276 0.0199 0.0249
std 0.1304 0.2107 0.2040 0.2143 0.2202 0.2159 0.2083 0.2165 0.2189 0.2091
II bias 0.1963 0.0053 0.0025 0.0039 0.0064 0.0072 0.0114 0.0114 0.0046 0.0070
std 0.4698 0.1242 0.1174 0.1223 0.1208 0.1190 0.1168 0.1131 0.1190 0.1211
III bias 0.0175 0.0323 0.0353 0.0356 0.0396 0.0329 0.0341 0.0381 0.0297 0.0385
std 0.0388 0.0986 0.0949 0.0976 0.0959 0.0917 0.0951 0.0939 0.0940 0.0930
IV bias 0.0358 -0.0019 -0.0014 0.0053 0.0048 0.0023 0.0024 0.0038 0.0041 0.0088
std 0.0909 0.1262 0.1267 0.1233 0.1262 0.1268 0.1250 0.1333 0.1203 0.1299
V bias 0.3581 0.0177 0.0353 0.0214 0.0366 0.0321 0.0322 0.0363 0.0371 0.0374
std 0.1620 0.2753 0.2620 0.2668 0.2638 0.2570 0.2539 0.2660 0.2699 0.2647
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Table 2.3: Simulation 3. Comparisons of different methods I, II, III, IV, and V when no condition is satisfied. Absolute bias
(bias) and sample standard deviation (std) are based on 1000 simulations with sample sizes n = 200 and n = 400.
Method β1 β2 β3 β4 β5 β6 β7 β8 β9 β10
n = 200
true -0.8980 -0.0898 -0.0449 0.0000 0.0449 0.0898 0.1347 0.1796 0.2245 0.2694
I bias 0.0879 -0.0830 -0.0387 -0.0154 -0.0025 0.0104 0.0235 0.0259 0.0193 0.0008
std 0.0684 0.0985 0.1015 0.1094 0.1064 0.1050 0.1004 0.0960 0.0897 0.0941
II bias 0.2490 0.0172 0.0155 0.0188 -0.0022 -0.0092 -0.0219 -0.0153 -0.0144 -0.0105
std 0.3302 0.1566 0.1269 0.1316 0.1341 0.1421 0.1736 0.2182 0.2409 0.2694
III bias 0.2593 0.0533 0.0406 0.0825 0.0124 -0.0149 -0.0023 -0.0041 -0.0066 0.0186
std 0.2122 0.1574 0.1363 0.2041 0.1314 0.1487 0.1883 0.2266 0.2576 0.2722
IV bias 0.2451 0.0020 -0.0367 -0.0826 -0.1335 -0.1665 -0.2192 -0.2580 -0.3080 -0.3548
std 0.4966 0.2042 0.2037 0.2137 0.2214 0.2450 0.2577 0.2742 0.2899 0.2870
V bias 0.3684 0.0787 0.0547 0.0157 0.0106 -0.0086 -0.0150 -0.0321 -0.0297 -0.0244
std 0.1539 0.2812 0.2805 0.2813 0.2758 0.2712 0.2816 0.2752 0.2542 0.2593
n = 400
true -0.8980 -0.0898 -0.0449 0.0000 0.0449 0.0898 0.1347 0.1796 0.2245 0.2694
I bias 0.0672 -0.0876 -0.0356 -0.0101 0.0036 0.0127 0.0242 0.0325 0.0289 0.0041
std 0.0509 0.0706 0.0752 0.0751 0.0733 0.0749 0.0727 0.0705 0.0692 0.0690
II bias 0.2219 0.0129 -0.0022 0.0020 0.0035 -0.0025 -0.0089 -0.0110 -0.0007 0.0064
std 0.3108 0.1432 0.1116 0.0707 0.0945 0.1218 0.1622 0.2132 0.2355 0.2631
III bias 0.1678 0.0283 0.0119 0.0220 -0.0036 -0.0133 -0.0121 0.0082 0.0178 0.0270
std 0.2100 0.1243 0.0907 0.1072 0.0810 0.1097 0.1564 0.1802 0.2066 0.2445
IV bias 0.1246 0.0061 -0.0481 -0.1019 -0.1551 -0.2246 -0.2771 -0.3340 -0.3929 -0.4595
std 0.3368 0.1275 0.1231 0.1360 0.1477 0.1505 0.1664 0.1937 0.1981 0.2003
V bias 0.2807 0.0983 0.0375 0.0350 0.0138 0.0049 -0.0026 0.0033 -0.0012 0.0223
std 0.1143 0.2320 0.2294 0.2275 0.2195 0.2290 0.2268 0.2293 0.2213 0.2172
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Table 2.4: Comparisons of different methods I, II, III, IV, and V using asthmatic data
in which only linearity condition holds. Absolute bias (bias) and sample standard
deviation (std) are based on 1000 generated datasets via parametric bootstrap with
sample size n = 827.
Method β1 β2
true 1.00000 0.00000
I bias -0.00040 -0.00097
std 0.00057 0.02828
II bias -0.00020 -0.00009
std 0.00018 0.02003
III bias -0.00010 -0.00005
std 0.00009 0.01447
IV bias 0.00234 -0.00073
std 0.03906 0.02922
V bias -0.00460 -0.00300
std 0.03960 0.12489
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Table 2.5: Comparisons of methods I, II, III, IV, and V on breast cancer data in
terms of AUCs. Estimation is based on a ten-fold crossvalidation: randomly selected
90% of the observations is used for a training sample and 10% for a testing sample
whose AUCs are computed. Various number of covariates from p = 2 to p = 35 are
included in the model.
Method p = 2 p = 5 p = 10 p = 15 p = 20 p = 25 p = 30 p = 35
I 0.5870 0.6879 0.6751 0.6867 0.7068 0.7115 0.7109 0.7160
II 0.5885 0.6902 0.6743 0.6781 0.6986 0.7042 0.7100 0.7150
III 0.5828 0.6831 0.6651 0.6793 0.6998 0.7084 0.6961 0.7062
IV 0.5998 0.6250 0.6033 0.6419 0.6377 0.6456 0.6056 0.6197
V 0.5762 0.6805 0.6455 0.6297 0.6326 0.6280 0.6315 0.6524
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Figure 2.1: Boxplots of MSE of method I, II, III, IV, and V in Simulations 1, 2 and
3. Results based on 1000 simulations.
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Figure 2.2: Boxplots of AUC of method I, II, III, IV and V in Simulations 1, 2 and
3. Results based on 1000 simulations.
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Figure 2.3: Simulation 1. Boxplots of β̂i. True βi value super-imposed by horizontal
line.
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Figure 2.4: Simulation 2. Boxplots of β̂i. True βi value super-imposed by horizontal
line.
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Figure 2.5: Simulation 3. Boxplots of β̂i. True βi value super-imposed by horizontal
line.
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Figure 2.6: Boxplots of MSE of method I, II, III, IV, and V in Simulations 1, 2 and
3. Results based on 1000 simulations with sample size n = 400.
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Figure 2.7: Boxplots of AUC of method I, II, III, IV and V in Simulations 1, 2 and
3. Results based on 1000 simulations with sample size n = 400.
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Figure 2.8: Boxplots of MSE of method I, II, III, IV, and V in asthmatic data.
Results based on 1000 parametric bootstrap samples.
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Figure 2.9: Boxplots of AUC of method I, II, III, IV, and V in asthmatic data.
Results based on 1000 parametric bootstrap samples.
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Figure 2.10: Left: scatter plot of a component ofX and β̂Tx on which a linear regres-
sion line is imposed. Right: scatter plot of the product of two residual components
against β̂Tx on which the a constant regression line is imposed.
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Chapter 3
Using Sufficient Direction Factor Model to
Analyze Breast Cancer Pathway Activities 1
Summary: Analysis of breast cancer survival data with gene expressions motivates
us to use a two-stage approach to model the association between survival time and
breast cancer pathway activity levels. In the first stage, based on five subtypes
and eight prominent pathways for breast cancer, we identify subtype-specific and
pathway-specific informative genes using factor model and estimate factor and loading
matrix for each cancer subtype. We further impose a sparsity condition such that
prior biological knowledge on relation between pathway activity levels and genes can
be incorporated in the model. In the second stage, we investigate the relationship
between pathway activity levels and survival time with censoring using a general
dimension reduction model in the survival analysis context. Combining the factor
model and sufficient direction model provides an efficient way to analyzing high-
dimensional data and reveals some interesting relations in the breast cancer study
data.
1Baek, S., Ho, Y.-Y., and Ma, Y. Using Sufficient Direction Factor Model to Analyze Breast
Cancer Pathway Activities, which has been submitted to Biometrics for publication and under
review.
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3.1 Introduction
Breast cancer is a molecular heterogeneous disease. In treating breast cancer,
tumor classification has been a clinically important component for the purpose of
diagnosis and prognosis. Based on gene expression profiling, it is a common practice to
classify breast cancer tumors into one of five subtypes—Basal, Her2-enriched, Luminal
B, Luminal A, and Normal-like (Cancer CGoHFiB, 2001). In order to understand the
heterogeneity of breast cancer, pathway analysis is widely used. Pathway analysis can
be applied to identify biological functions for groups of related genes (García-Campos
et al., 2015). One of the main goals of this study is to estimate pathway activity
levels for each patient using observed high-dimensional gene expression measurements,
while taking into account of breast cancer subtypes. A second goal is to study how
the different breast cancer pathway activity levels jointly affect the survival time of
the cancer patients. The two goals are achieved through an integrated procedure
consisting of two stages.
In the first stage, we estimate the pathway activity levels through a factor model
that is breast cancer subtype-specific. Such factor model is then made more complex
because we further integrated the biological knowledge that certain gene expressions
are not influenced by some specific pathways. In the second stage, we use a very
general sufficient dimension reduction model to describe the influence of the individ-
ual specific pathway activity levels on the survival time, while taking into account
censoring. Some main features of our treatment are summarized below.
In analyzing the relation of the pathway activity levels and the gene expression
levels, the pathway activity levels are usually unknown and can be different for each
patient. Hence they have to be treated as latent in our analysis. For breast cancer,
there are eight pathways that are commonly believed to be relevant based on KEGG
pathway database (KEGG, 1995). On the other hand, expression levels are usually
measured at thousands or even more genes. This provides an ideal setting for a factor
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model approach, where, as a first stage model, we assume that the gene expression
levels are linked to the unavailable individual pathway activity levels through a linear
relation up to an additive noise. The unavailable pathway activity levels are hence
the latent factors, while the gene expression levels of a patient form a vector of
observations. In addition to the natural fit of the factor model in linking the gene
expression levels and the pathway activity levels, the factor model has the additional
advantage of reducing the effective dimensionality from the number of expression
levels, which is 19,149 in our specific breast cancer data example, to the number of
pathway activity levels which is 8 for breast cancer. This feature is also exploited in
Fan et al. (2017) and Jiang et al. (2017).
In addition to the standard factor analysis model, we further incorporate two ad-
ditional features. The first is to allow breast cancer subtype-specific loading matrices.
This allows the linear association between pathway activity levels and the exhibited
gene expression levels to be different for each breast cancer subtype, hence it enables
to increase the interpretability and flexibility of the model. Second, we impose a
sparsity assumption on the loading matrices. The purpose of this assumption is to
incorporate the prior biological knowledge that the expression levels of certain genes
can be irrelevant to one or more pathways hence the corresponding entries in the load-
ing matrix should be shrunk to zero. The sparsity assumption is taken into account
in our factor model analysis procedure through incorporating an L1 penalty in terms
of methodology, and is achieved via an Alternating Direction Method of Multipliers
(ADMM) optimization procedure in terms of computation.
Even with the successful estimation of the pathway activity levels of each patient,
it is still not a straightforward task to link these pathway activity levels to the breast
cancer survival. This is due to the unclear functional relation between the patient
survival time and his/her individual pathway activity levels. We hence restrain from
imposing any specific survival model and leave the functional form nonparametric. On
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the other hand, even when dealing with a seemingly small number of eight pathways,
our estimation is still subject to the curse of dimensionality due to the nonparametric
nature of the relation. In addition, besides the pathway activity levels, certain co-
variates are known to directly link to the survival times of breast cancer patients. For
example, the highest breast cancer incidence rates for white women are among the
group aged 40 and above (DeSantis et al., 2014). We thus need to include the ages
of patients as a clinically relevant variable and incorporate it into the model as well.
Thus, as a second stage model, we adopt the flexible sufficient dimension reduction
approach. We assume the pathways together with age form several linear combi-
nations, and these combinations jointly affect the survival time in a nonparametric
way. We will use the data to determine what is the appropriate number of the linear
combinations, what are these combinations and what is the eventual functional form.
To further take into account the censoring nature of the survival times, we incorpo-
rate the Martingale technique in combination with semiparametric treatment (Zhao
et al., 2017) to provide a consistent estimator that is optimal in terms of achieving
the smallest possible estimation variability.
The remainder of this paper is organized as follows. In Section 3.2, we provide
details of the modeling and estimating methodologies to analyze the breast cancer
data. We demonstrate the finite sample performance of our methods through exten-
sive simulation studies in Section 3.3. In Section 3.4, we carry out the analysis of the
breast cancer data from the the International Cancer Genome Consortium (ICGC)
(Cancer Genome Atlas Network 2012; Zhang et al. 2011), interpret our results and
draw scientific conclusions. Lastly, in Section 3.5 we conclude this work with some
discussions. A summary of asymptotic properties for the estimator relevant to this
study and some additional numerical results are relegated to the Appendix.
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3.2 Methodological Development
Data structure and modeling
To be specific, we describe the structure of the data that we consider in this work
and our modeling strategy. Although the model is directly motivated by the breast
cancer data, it is sufficiently general and can be applied in similar problems as well.
Let the independent and identically distributed (iid) observations (Xi, Yi,∆i, Zi,
Wi), i = 1, . . . , n, measured from n patients. Here, Xi ∈ Rp is the vector of the
gene expressions of the ith patient measured on p genes. For the breast cancer data
that we consider, n = 978 and p = 19149. Let Ti be the time to event and Ci be the
censoring time for the ith patient, then Yi = min(Ti, Ci) and ∆i = I(Ti < Ci). It
is a common practice to classify the breast cancer tumors into one of five subtypes
(Parker et al. 2009; Cancer Genome Atlas Network 2012), and we use Zi to represent
the breast cancer subtype of patient i. There are five categorical values that Zi can
be in our data: 1 (Basal), 2 (Her2-enriched), 3 (Luminal B), 4 (Luminal A) and
5 (Normal-like). In more general setting, we can view Zi as a stratification index
with, say K, different categories, and Zi can be correlated with Xi. Finally, Wi
contains additional covariates that are known to affect the time to event Ti. In the
breast cancer study, Wi contains age because of its known causal effect on survival
(DeSantis et al., 2014).
Let the pathway activity levels of patient i be fi ∈ Rq, q > p. In breast can-
cer, there are eight commonly adopted breast cancer pathways according to Kyoto
Encyclopedia of Genes and Genomes (Kanehisa and Goto, 2000): estrogen signal-
ing pathway, MAPK signaling pathway, PI3K-Akt signaling pathway, p53 signaling
pathway, notch signaling pathway, Wnt signaling pathway, cell cycle pathway, and
Homologous recombination pathway. Hence we set q = 8. Note that fi is not observ-
able. We employ a two-stage model to analyze the dependence of the breast cancer
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survival on patient genetic information. We first stratify gene expressions Xi based
on cancer subtype Zi, and then model the relationship between Xi and the pathway
activity levels fi within each stratum using a factor model:
Xi = Bkfi +Ui when Zi = k, (3.1)
where fi ∈ Rq, Ui ∈ Rp, and Bk ∈ Rp×q is a subtype-specific loading matrix. For
identifiability reason and to keep the interpretation simple, we assume the pathway
activity levels are uncorrelated with each other and are standardized to have variance
1, and the columns of Bk are uncorrelated. Thus, we assume cov(fi) = Iq and BTkBk
is diagonal for all k = 1, . . . , K. Of course this may not be the case in reality, since
in reality, pathways are often formed by groups of genes and they may not contribute
to standardized and mutually uncorrelated effects. In this case, we in fact have
B∗kf∗i = (BkM−1)(Mfi), where f∗i = Mfi is the true pathway activity levels and fi can
be viewed as a rotated and standardized version of the true pathway activity levels.
Second, we model the impact of fi and Wi on Ti through
pr(Ti < t | fi,Wi) = h(t,βTfi +αTWi), (3.2)
where β ∈ Rq×d with d < q, α ∈ Rdim(W)×d, and h is an unspecified smooth condi-
tional cumulative distribution function. The stage 1 model in (3.1) and the stage 2
model in (3.2) jointly fully describe our modeling strategy for the breast cancer data
analysis.
Estimation of pathway activity levels in stage 1 model
In the first stage, we estimate individual pathway activity levels based on breast
cancer subtypes, which results in estimating subtype-specific loading matrices. To
this end, we stratify the samples into five strata according to the Zi values, with the
data in the kth stratum having Zi = k for all i. In each stratum, we perform the
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following analysis. For simplicity of notation, we omit the stratum index k and write
the analysis as if there were only one stratum.
Let X = (X1, . . . ,Xn), F = (f1, . . . , fn), U = (U1, . . . ,Un). Hence the factor
model (3.1) is summarized as X = BF + U. We can interpret the relation as the
following. The expression level of Xij is linearly related to the activity levels of
different pathways, plus some random noise captured in Uij. If we do not impose
any additional knowledge on B, then B and fi can be estimated using the Singular
Value Decomposition (SVD) as in the classical factor model. This is equivalent to
minimizing the Frobenious norm of X−BF. In our context, we thus naturally extend
the SVD to solving minB,F ‖X−BF‖2F subject to the constraints thatBTB is diagonal
and FFT = Iq.
In breast cancer studies, some further prior knowledge is available, which enables
us to believe to a good extent that certain genes belong to some specific pathways
while they have very little relation with some other pathways. For example, the
tumor suppressor gene PTEN interacts mainly with the PI3K-Akt signaling path-
way, while it is known to have very little to none interaction with all other pathways
among the eight pathways of our interest (Stemke-Hale et al., 2008). To incorporate
such knowledge, we impose additional sparsity condition on B through incorporat-
ing penalty. For example, using Lasso penalty, we solve the minimization problem
minB,F n−1‖X − BF‖2F + λ
∑q
i=1 ‖Bi−‖1, where Bi− represents the ith column of B
with some components that we do not want to shrink to zero excluded. For example,
if the first pathway is known to affect the first 10 gene expression values for sure, while
it is not so certain to be related to the expression values of the remaining genes, then
we would set B1− = (B11,1, . . . , Bp,1)T.
In terms of computation, we perform the following procedure.
• Step 0: Ignore the sparsity constraints and perform SVD. Use the corresponding
F˜ and B˜ as starting values.
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• Step 1: Iteratively solve for B with F fixed at the current estimated value and
solve for F with B fixed at the current estimated value.
Step 1a: WhenB is fixed, say atB(k−1), solving for F is a standard minimization
problem in a quadratic function. So F has the closed form solution, F(k) =
{B(k−1)TB(k−1)}−1B(k−1)TX.
Step 1b: When F is fixed, say at F(k), solving for B is a quadratic minimization
problem with L1 penalty, which can be solved by using Alternating Direction
Method of Multipliers (ADMM) procedure.
Case of Bi− = Bi
In ADMM form, the problem can be rewritten as
min
B,C
n−1‖X−BF(k)‖2F + λ
q∑
i=1
‖Ci‖1,
subject to B−C = 0,
which is equivalent to minimizing
Lρ(B,C,Y) = n−1‖X−BF(k)‖2F +
q∑
i=1
yTi (Bi −Ci) +
ρ
2
q∑
i=1
‖Bi −Ci‖22
+λ
q∑
i=1
‖Ci‖1,
where yi is a p× 1 vector and Y = (y1, · · · ,yq) is a p× q matrix. For a fixed
C(j−1) and Y(j−1), we have
B(j) = argminBLρ(B,C(j−1),Y(j−1))
= argminB
{
n−1‖X−BF(k)‖2F +
q∑
i=1
y(j−1)i
T
Bi +
ρ
2
q∑
i=1
‖Bi −C(j−1)i )‖22
}
= argminB
[
n−1trace{(X−BF(k))T(X−BF(k))}+ trace(Y(j−1)TB)
+ρ2trace{(B−C
(j−1))T(B−C(j−1))}
]
.
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Thus,
0 = ∇B
[
n−1trace{(X−BF(k))T(X−BF(k))}+ trace(Y(j−1)TB)
+ρ2trace{(B−C
(j−1))T(B−C(j−1))}
]
= −2n−1XF(k)T + 2n−1BF(k)F(k)T +Y(j−1) + ρ(B−C(j−1)),
hence
B(j) = (2n−1XF(k)T −Y(j−1) + ρC(j−1))(2n−1F(k)F(k)T + ρIq)−1.
For a fixed B(j) and Y(j−1), we have
C(j) = argminCLρ(B(j),C,Y(j−1))
= argminC
{
−
q∑
i=1
y(j−1)i
T
Ci +
ρ
2
q∑
i=1
‖B(j)i −Ci‖22 + λ
q∑
i=1
‖Ci‖1
}
= argminC
q∑
i=1
p∑
l=1
{
−Y (j−1)il Cil +
ρ
2(B
(j)
il − Cil)2 + λ|Cil|
}
,
whereBil and Cil are (i, l) elements ofB andC, respectively. The subdifferential
is
∂
{
−Y (j−1)il Cil +
ρ
2(B
(j)
il − Cil)2 + λ|Cil|
}
/∂Cil
=

λ− Y (j−1)il − ρ(B(j)il − Cil), if Cil > 0
−λ− Y (j−1)il − ρ(B(j)il − Cil), if Cil < 0.
Thus
Cil
(j) =

Bil
(j) + ρ−1(Yil(j−1) − λ), if Bil(j) > ρ−1(−Yil(j−1) + λ)
Bil
(j) + ρ−1(Yil(j−1) + λ), if Bil(j) < ρ−1(−Yil(j−1) − λ)
0, if Bil(j) ∈ [ρ−1(−Yil(j−1) − λ),
ρ−1(−Yil(j−1) + λ)].
To update Y, we set
Y(j) = Y(j−1) + ρ(B(j) −C(j)).
47
Case of Bi− 6= Bi
In this case, we leave some components in B unpenalized based on our prior
knowledge. Bi− stands for the ith column of B with some components to be
penalized. Also, we define Ai to be an index set for penalized components of ith
column. For example, if B1− = (B11,1, · · · , Bp,1)T, then A1 = {11, 12, · · · , p}.
In ADMM form, the problem can be rewritten as
min
B,C
n−1‖X−BF(k)‖2F + λ
q∑
i=1
‖Ci−‖1,
subject to B−C = 0,
which is equivalent to minimizing
Lρ(B,C,Y) = n−1‖X−BF(k)‖2F +
q∑
i=1
yTi (Bi −Ci) +
ρ
2
q∑
i=1
‖Bi −Ci‖22
+λ
q∑
i=1
‖Ci−‖1.
where yi is a p× 1 vector and Y = (y1, · · · ,yq) is a p× q matrix. For a fixed
C(j−1) and Y(j−1), we have
B(j) = argminBLρ(B,C(j−1),Y(j−1))
= argminB
{
n−1‖X−BF(k)‖2F +
q∑
i=1
y(j−1)i
T
Bi +
ρ
2
q∑
i=1
‖Bi −C(j−1)i )‖22
}
= argminB
[
n−1trace{(X−BF(k))T(X−BF(k))}+ trace(Y(j−1)TB)
+ρ2trace{(B−C
(j−1))T(B−C(j−1))}
]
.
Therefore,
0 = ∇B
[
n−1trace{(X−BF(k))T(X−BF(k))}+ trace(Y(j−1)TB)
+ρ2trace{(B−C
(j−1))T(B−C(j−1))}
]
= −2n−1XF(k)T + 2n−1BF(k)F(k)T +Y(j−1) + ρ(B−C(j−1)),
hence,
B(j) = (2n−1XF(k)T −Y(j−1) + ρC(j−1))(2n−1F(k)F(k)T + ρIq)−1.
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For a fixed B(j) and Y(j−1), we have
C(j) = argminCLρ(B(j),C,Y(j−1))
= argminC
{
−
q∑
i=1
y(j−1)i
T
Ci +
ρ
2
q∑
i=1
‖B(j)i −Ci‖22 + λ
q∑
i=1
‖Ci−‖1
}
= argminC
q∑
i=1
p∑
l=1
{
−Y (j−1)il Cil +
ρ
2(B
(j)
il − Cil)2 + λ|Cil|I(l ∈ Ai)
}
,
where I(·) is an indicator function and Bil and Cil are (i, l) elements of B and
C, respectively. The subdifferential is
∂
{
−Y (j−1)il Cil +
ρ
2(B
(j)
il − Cil)2 + λ|Cil|I(l ∈ Ai)
}
/∂Cil
=

λI(l ∈ Ai)− Y (j−1)il − ρ(B(j)il − Cil), if Cil > 0
−λI(l ∈ Ai)− Y (j−1)il − ρ(B(j)il − Cil), if Cil < 0.
Thus, if l /∈ Ai, then
Cil
(j) = Bil(j) + ρ−1Yil(j−1),
and if l ∈ Ai, then
Cil
(j) =

Bil
(j) + ρ−1(Yil(j−1) − λ, if Bil(j) > ρ−1(−Yil(j−1) + λ)
Bil
(j) + ρ−1(Yil(j−1) + λ), if Bil(j) < ρ−1(−Yil(j−1) − λ)
0, if Bil(j) ∈ [ρ−1(−Yil(j−1) − λ),
ρ−1(−Yil(j−1) + λ)].
To update Y, we set
Y(j) = Y(j−1) + ρ(B(j) −C(j)).
• Step 2: Stop the procedure when convergence is achieved.
Estimation of survival model in stage 2 model
We now establish the relationship between breast cancer survival and pathway
activity levels and other covariates that are linked to breast cancer survival. To this
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end, we treat f∗i = (fTi ,Wi)T in the second stage model as covariates, where fi is
individual pathway activity levels andWi contains age. Letting γ = (βT,αT)T, then
we can write (3.2) succinctly as
pr(Ti < t|f∗i ) = h(t,γTf∗i ), (3.3)
where γ ∈ R{q+dim(Wi)}×d.
The second stage model (3.3) merits some remarks. First, we employ d linear
summaries by the d columns of γ, which gives the flexibility for the association
among components of fi and Wi. Second, by leaving the link function h(·) in (3.3)
unspecified, we can avoid problems that stem from the mis-specification of a model.
In order for γ to be identifiable, we parameterize it so that the upper d × d block
matrix of γ is the identity matrix Id. For convenience, we write f∗ = (f∗u
T, f∗l
T)T,
where f∗u ∈ Rd and f∗l ∈ R{q+dim(Wi)}−d.
Combining semiparametric treatment and martingale process, Zhao et al. (2017)
proposed a estimation procedure for censored survival data that is consistent, asymp-
totically normal and semiparametric efficient, without imposing any assumption on
the conditional distribution of the censoring time given covariates. We use this pro-
cedure to obtain the semiparametric efficient estimator by solving the following esti-
mating equations
n∑
i=1
∆i
λ̂1(Yi,γTf∗i )
λ̂(Yi,γTf∗i )
⊗
[
f∗li −
Ê{f∗liUi(Yi)|γTf∗i }
Ê{Ui(Yi)|γTf∗i }
]
= 0, (3.4)
where λ̂(·) is the esimated hazard function, λ̂1(·) is the derivative of λ̂(·) with respect
to γTf∗, and U(t) = I(Y ≥ t). More specifically,
λ̂(Y,γTf∗) =
n∑
i=1
Kb(Yi − Y ) ∆iKh(γ
Tf∗i − γTf∗)∑n
j=1 I(Yj ≥ Yi)Kh(γTf∗j − γTf∗)
, (3.5)
λ̂1(Y,γTf∗) = ∂λ̂(Y,γTf∗)/∂(γTf∗), (3.6)
where K(·) is a kernel function, Kh(·) = K(·/h)/h and h is a bandwidth. K′h(v) is
the first derivative of Kh(v) with respect to v, and b is also a bandwidth. Similarly,
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using kernel estimation, we let
Ê{f∗liUi(Yi)|γTf∗i } =
∑n
j=1Kh(γTf∗j − γTf∗i )f∗ljI(Yj ≥ Yi)∑n
j=1Kh(γTf∗j − γTf∗i )
, (3.7)
Ê{Ui(Yi)|γTf∗i } =
∑n
j=1Kh(γTf∗j − γTf∗i )I(Yj ≥ Yi)∑n
j=1Kh(γTf∗j − γTf∗i )
, (3.8)
where E{Ui(Yi)|γTf∗i } ≡ E{Ui(t)|γTf∗i }|t=Yi . Inserting (3.5), (3.6), (3.7) and (3.8)
into (3.4), we can solve the estimating equation and the solution is the semiparametric
efficient estimator of γ.
The nonparametric estimators given in (3.5), (3.6), (3.7) and (3.8) require band-
width selection. As noted in Assumption A2 in Appendix B.1, a wide range of
bandwidths can be used and it does not affect the asymptotic property, i.e., the final
estimator γ̂ is insensitive to the bandwidth selection. For example, we can select the
bandwidths by taking the sample size n to a suitable power for which Assumption
A2 holds, and multiply a constant, such as the variance of the covariates, for proper
scaling. We refer to Zhao et al. (2017) for more specific guidelines on bandwidth
selection.
Zhao et al. (2017) showed the consistency and asymptotic properties of the ef-
ficient estimator obtained by solving the estimating equations (3.4) under Assump-
tions A1-A7 in Appendix B.1. In summary, γ̂ − γ0 = op(1) and
√
n(γ̂ − γ0) →
N (0, [E{S⊗2eff (∆, Y, f∗)}]−1) in distribution, where γ0 is the true parameter, and Seff is
the efficient score with its specific form given in the Appendix B.2, and a⊗2 ≡ aaT for
any vector or matrix a. These asymptotic properties are provided through Theorems
1 and 2 in the Appendix B.2 for convenience. See Zhao et al. (2017) for their proofs.
3.3 Simulations
Before applying our modeling and estimation methods to analyze the breast cancer
data, we first carry out simulations to evaluate the finite sample performance of the
methods. All the simulation results are based on 1000 datasets.
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In Simulation 1, we consider two strata (K = 2) for the stage 1 model. We fix
Zi = 1 for i = 1, . . . , n1, and Zi = 2 for i = n1 + 1, . . . , n1 + n2. The sample size
for each stratum is n1 = n2 = 250, resulting in n = 500. We let p = 200, q = 4
and d = 1. For each i = 1, . . . , n, we simulate fi from the q-dimensional multivariate
standard normal distribution and further generate a p × 1 random vector Li as the
following. When Zi = 1, we simulate Li from the p-dimensional multivariate standard
normal distribution. When Zi = 2, we simulate Li from a p-dimensional multivariate
normal distribution with mean 0 and variance-covariance matrix ΣL, where the (i, j)
element of ΣL is 0.5|i−j| for 1 ≤ i, j ≤ p. To construct the factor loading matrix
Bk for each stratum from (3.1), we perform eigen decomposition on the matrix LLT,
where L = (L1, · · · ,Ln)T. We let E1 be the n × q orthogonal matrix formed by the
eigenvectors corresponding to the q largest eigenvalues of LLT, and let E2 be the n×q
orthogonal matrix formed by the eigenvectors corresponding to the (q + 1)th to the
2qth largest eigenvalues of LLT. We then formBk = n−1/2LTEk, for k = 1, 2. Because
the eigenvectors corresponding to a symmetric matrix are orthogonal to each other,
this construction ensures that BTkBk is diagonal. We further generate Uis from a
p-dimensional multivariate normal distribution with mean 0 and variance-covariance
matrix 0.5Ip and then form Xi = Bkfi+Ui when Zi = k, for k = 1, 2, i = 1, . . . , n. To
further generate data in the stage 2 model, we set dim(Wi) = 1, and generateWi from
a standard normal distribution. We then form a new covariate f∗i = (fTi ,Wi)T ∈ Rq+1.
We now generate event times from
T = |γ
Tf∗|
2 + (γTf∗ + 1.5)2 + 0.5,
where  is uniformly distribution on (0, 1), and γ = (1, 0, 0.3,−0.3,−1)T. We further
generate the covariate dependent censoring times using Ci = Φ(2f ∗i2+2f ∗i3)+c1, where
c1 is used to control the proportion of censoring.
We design Simulation 2 so that it resembles the breast cancer data. Based on
the five breast cancer subtypes in this study and the eight common breast cancer
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pathways, we generate a data set with five (K = 5) strata, each of size nk, k = 1, . . . , 5,
and we set q = 8 and d = 1. We let n1 = 0.17n, n2 = 0.11n, n3 = 0.40n, n4 = 0.23n,
and n5 = 0.09n, so n =
∑5
k=1 nk. Unlike Simulation 1, we conduct this simulation
under different n and p combinations, as described below. We perform the simulation
studies under three different sizes, where (p, n) = (50, 100), (p, n) = (200, 500) and
(p, n) = (19000, 1000) respectively. In each combination of the p and n values, the
simulation was repeated 1000 times. The last case with (p, n) = (19000, 1000) is
designed to reflect the situation of the breast cancer data. For each i = 1, . . . , n,
we generate fi from a q-dimensional standard normal distribution. To generate the
factor loading matrices Bk such that BTkBk is diagonal, for k = 1, . . . , 5, we make
use of the property that the eigenvectors of a symmetric matrix are orthogonal to
each other. Since we consider five strata in Simulation 2, the symmetric matrix we
simulate has more complex structure. We first simulate n mean-zero p-dimensional
normal random vectors Li, i = 1, . . . , n. Here the variance-covariance matrix of Li
depends on the stratum it belongs to. Let the variance-covariance matrix be ΣL,k in
stratum k, for k = 1, . . . , 5. Then, we set the (j1, j2) element of ΣL,1 to be 0.3|j1−j2|,
ΣL,2 to be 0.5|j1−j2|, ΣL,4 to be 0.7|j1−j2|, and ΣL,5 to be 0.9|j1−j2|, for 1 ≤ j1, j2 ≤ p,
We let ΣL,3 be the identity matrix, i.e., ΣL,3 = Ip. By establishing a symmetric
matrix LLT and conducting eigen decomposition, we can construct a p × p matrix
whose columns correspond to the eigenvectors of LLT, where L = (L1, · · · ,Ln)T.
Now we form the factor loading matrix for each stratum as Bk = n−1/2LTEk, for
k = 1, . . . , 5. Here Ek is the n × q orthogonal matrix, and its columns are formed
by the q eigenvectors corresponding to (kq − q + 1)-th to kq-th largest eigenvalues
of LLT. Clearly, this procedure guarantees that BTkBk is diagonal. A p-dimensional
random noise vector Ui is further generated from a mean-zero multivariate normal
distribution with variance-covariance matrix 2Ip. Plugging all simulated components
into Xi = Bkfi +Ui, we obtain a p×n matrix X. We set dim(Wi) = 4 and simulate
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the three variables Wi1, Wi2 and Wi3 from a Bernoulli distribution with parameters
0.5, 0.6, and 0.7, respectively, and Wi4 from the standard normal distribution. This
is a more complex setting than the breast cancer data, which contains only a one
dimensional Wi. Event times are generated as follows:
T = exp{0.2γTf∗ + },
where  is uniformly distributed on (0, 1), and γ = (1, 0.2, 0.3, 0.5,−0.5,−0.3,−0.2,
−1, 0.2, 0.2,−0.1, 0.1)T. The censoring time is generated from a uniform distribution
on (0, c), where c controls the proportion of censoring.
We provide the estimates, absolute biases, and sample standard deviations in Ta-
ble 3.1 for Simulation 1, and in Table 3.2 for Simulation 2, respectively. For both
simulations, we consider three different censoring rates: no censoring, 20%, and 40%
censoring. Across all simulations, the estimators have very small biases. It is not sur-
prising that the variability of the estimators under no censoring is in general smaller
compared to the cases with censoring. Further as p and n increase in Simulation 2,
the estimation performance improves in terms of the Euclidean distances ‖γ̂−γ‖, as
shown in Figure 3.1.
3.4 Application
We now apply the two-stage modeling and estimation procedure to the breast can-
cer survival data. We downloaded breast cancer data from The Cancer Genome Atlas
(TCGA) project via the ICGC controlled data portal (https://dcc.icgc.org/releases/
release_26/Projects/BRCA-US). The data contains 978 female patients with infor-
mation for gene expression, age, and survival/follow-up time. Following Parker et al.
(2009), we categorize the patients in the study into five subtypes: Basal (185, 18.9%),
Her2-enriched (107, 10.9%), Luminal B (428, 43.8%), Luminal A (248, 25.4%), and
Normal-like (10, 1.0%). Among the 978 patients, only 100 events are observed, while
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the remaining 878 are censored, hence the censoring rate is about 89.8%. For each
patient, expression levels at 19,149 genes are measured, i.e., p = 19, 149. In addition,
we include age as the covariate W in the second stage model due to its potential
association with breast cancer survival. Inspired by the fact that genetic networks
(Gardner et al., 2003) are sparse, we incorporate sparsity condition of B using Lasso
penalty, except for 132 breast cancer related-genes reported in the KEGG database.
The list of these 132 genes can be found in B.1.
During the analysis, the number of pathways is fixed at q = 8, representing
the eight commonly known pathways, while the dimension of the reduced space d is
selected via Validated Information Criterion (VIC), where the candidate dimension at
which the VIC value is minimized is chosen as d (Ma and Zhang, 2015). Specifically,
for the breast cancer data, the VIC value at d = 1 is 62.05, whereas the VIC values
are all greater than 124.27 when d ≥ 2. Thus we select d = 1.
We performed the estimation procedure following the description in Section 3.2
and also estimated the variability of the estimates through 1000 bootstrap samples.
We provide the final results in Table 3.3, showing that all pathway activity levels
are statistically significant in terms of their relation with survival time, with p-values
ranging from 0.0045 to 0.0192. However, having adjusted for the pathway activity
levels, age is no longer a significant factor, with its p-value more than 0.5. In addition,
our results illustrate that the latent factors 2 and 5 would have effects on the time to
event T in the opposite direction to the other factors. Compared to the latent factor
1, the magnitude of all other factors affecting the time to event varied from 1.7 to 2.5,
for example the fourth factor has the magnitude of 1.9. Furthermore, for example,
since the coefficient of the latent factor 3 from Table 3.3 is positive, we can expect
that the cumulative hazard would decrease with increasing value of the latent factor
3 while holding all other pathway activity levels fixed.
The estimated hazard function Λ̂(t,βTf+αTW) is plotted in Figure 3.2 for four
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cancer subtypes including Basal, Her2-enriched, Luminal B and Luminal A. Because
no terminal events were observed in the Normal-like cancer patients, we do not provide
results for this cancer subtype. The upper-left panel in Figure 3.2 illustrates the plot
of Λ̂ as a function of t while the pathway activity levels are fixed at the respective mean
value index value β̂Tfi + α̂TWi for each cancer subtype. Compared to other cancer
subtypes, the cancer subtype Her2-enriched shows much higher estimated cumulative
hazard at almost all times, suggesting a much high risk of event. The other three
panels contain plots of Λ̂ as a function of the index βTf + αTW while t is fixed
at 600, 1200 and 3000 respectively. These three plots illustrate that the cumulative
hazard function is generally a decreasing function of the index βTf + αTW. In
addition, we provide contour plots of Λ̂ in Figure 3.3 as a function of both t and the
index βTf + αTW for the four cancer subtypes. The numbers in the plots are the
values of Λ̂ on the contour. It shows that Her2-enriched cancer subtype has relatively
high cumulative hazard.
We now describe more explicitly the latent factors fi’s which we have named
pathway activity levels. In Figure 3.4, we observe that in the p53 signaling pathway,
across all cancer subtypes, the similar genes seem to have the largest impact on the
overall pathway activity levels, reflected by brighter stripes in the same positions in
these heatmaps. In addition, the right side-bar represents the L2 norm square of each
row in the loading matrix B. Quantitatively, the Basal cancer subtype, the Her2-
enriched cancer subtype and the Normal cancer subtype have more similar patterns,
in that they share the same top two leading genes in terms of their impact from the
pathway activity levels. The Luminal A cancer subtype shares the first three leading
genes, but in reverse order for the second and third genes. The Luminal B cancer type
is more different from the rest subtypes. Its leading gene matches with the second or
third leading gene in other cancer types. To show this analysis more clearly, in Table
3.4, we present top five genes in the p53 pathway that have the largest joint pathway
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activity levels, i.e., genes with the five highest L2 norm squares—the top brightest
five genes indicated in the right side-bars by the heatmaps in their corresponding
loading matrix for p53 signaling pathway in each cancer subtype. To facilitate a
better comparison with Figure 3.4, we provide the location of top five selected genes
and their corresponding joint pathway activity levels in log-scale. We find that the
genes detected in Table 3.4 have biological meanings and play significant roles in
breast cancer. For example, CCND1 encodes the cyclin D1 protein whose activity is
necessary for the control of proliferation (Carvalho et al., 2008). PERP and IGFBP3
have the function of apoptosis and survival, and THBS1 plays a role as angiogenesis
(Lacroix et al., 2006). Similar plots and tables for the remaining seven pathways are
provided in Figures B.1 to B.7 and Tables B.2 to B.8 in the Appendix.
Finally, in Table 3.5, we calculate the average overall strength of the joint pathway
activity levels of all genes belonging to each signaling pathway. These are calculated
as averages of L2 norm squares of all genes in each corresponding pathway for cancer
subtype k, where k = 1, . . . , 5, which is presented in log-scale. From this table, we
notice that genes in p53 pathway have the largest overall strength of joint pathway
activity levels on Luminal B on average.
3.5 Discussion
We have adopted a framework for analyzing high-dimensional breast cancer sur-
vival data by combining factor model and flexible sufficient direction method. There
are several features and corresponding benefits. First, for different cancer subtypes,
we employ a stratified approach using factor model, i.e., the estimation of factor and
loading matrix hinges upon each cancer subtype. This enables us to identify subtype-
specific and pathway-specific significant genes in terms of the overall strength of joint
pathway activity levels. Second, we incorporate the prior sparsity knowledge on the
factor loading matrix using L1 penalty, which helps to reduce the number of none zero
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elements to be estimated in the loading matrix. Third, a very flexible general index
model is used in our second stage model which only requires minimal assumptions.
This is important because when we form a model using latent factors as covariates,
it can be more susceptible to model misspecification.
As an extension of the second merit in the above, we can consider more general
model if further knowledge on data structure is available. For example, if it is known
that q1 of pathway activity levels among the q pathway activity levels are common
to all strata and q − q1 are different from one anther for each stratum, it is not hard
to extend the first stage model (3.1) to the following:
Xi = (C,Bk)fi +Ui when Zi = k,
where C is a p× q1 matrix that captures the common pathway activity levels across
strata, whileBk is a p×(q−q1) matrix captures the stratum-specific pathways activity
levels. All procedures we exploited in this paper can be extended to this general case.
In this study, we use eight well-known pathways and therefore assume that the
number of factors is eight. If there is no prior knowledge to pre-assign the number
of factors in (3.1), one should first determine the number of factors. A large body of
literature provides many estimation methods for determining the number of factors
(Ahn and Horenstein 2013; Bai and Ng 2002; Lam et al. 2012; Luo and Li 2016),
which may be adapted to the high-dimensional genomic data problems.
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Table 3.1: Simulation 1. Estimates (est), absolute bias (bias) and sample stan-
dard deviation (std) based on 1000 simulations. p = 200, n = 500. γ =
(1, 0, 0.3,−0.3,−1)T.
est bias std est bias std est bias std
No censoring 20% censoring 40% censoring
γ2 0.0022 0.0022 0.0856 -0.0006 0.0006 0.1320 0.0014 0.0014 0.0778
γ3 0.3006 0.0006 0.0877 0.2993 0.0007 0.0850 0.2990 0.0010 0.0845
γ4 -0.2983 0.0017 0.0759 -0.3009 0.0009 0.0865 -0.2975 0.0025 0.0782
γ5 -1.0017 0.0017 0.1045 -1.0099 0.0099 0.1919 -1.0031 0.0031 0.0780
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Table 3.2: Simulation 2. Estimates (est), absolute bias (bias) and sam-
ple standard deviation (std) based on 1000 simulations, under three different
(p, n) combinations: (p, n) = (50, 100), (200, 500) and (19000, 1000). γ =
(1, 0.2, 0.3, 0.5,−0.5,−0.3,−0.2,−1, 0.2, 0.2,−0.1, 0.1)T.
est bias std est bias std est bias std
No censoring 20% censoring 40% censoring
p = 50 and n = 100
γ2 0.2082 0.0082 0.1503 0.1912 0.0088 0.5661 0.2070 0.0070 0.6360
γ3 0.3008 0.0008 0.1233 0.3105 0.0105 0.3419 0.3159 0.0159 0.3409
γ4 0.4965 0.0035 0.1117 0.4971 0.0029 0.6184 0.4876 0.0124 0.4220
γ5 -0.5007 0.0007 0.1038 -0.4930 0.0070 0.6187 -0.4956 0.0044 0.3495
γ6 -0.2912 0.0088 0.1805 -0.2820 0.0180 0.4304 -0.2977 0.0023 0.4091
γ7 -0.2009 0.0009 0.1367 -0.1994 0.0006 0.2994 -0.2156 0.0156 0.3610
γ8 -1.0017 0.0017 0.0938 -1.0109 0.0109 0.6967 -0.9941 0.0059 0.5047
γ9 0.2161 0.0161 0.2210 0.1684 0.0316 1.6137 0.2048 0.0048 1.1404
γ10 0.2066 0.0066 0.1922 0.3155 0.1155 3.2384 0.2077 0.0077 0.9585
γ11 -0.0916 0.0084 0.1820 -0.0866 0.0134 1.3041 -0.1261 0.0261 0.7578
γ12 0.1026 0.0026 0.1122 0.1029 0.0029 1.5037 0.1421 0.0421 0.4783
p = 200 and n = 500
γ2 0.2082 0.0082 0.1503 0.1912 0.0088 0.5661 0.2070 0.0070 0.6360
γ3 0.3008 0.0008 0.1233 0.3105 0.0105 0.3419 0.3159 0.0159 0.3409
γ4 0.4965 0.0035 0.1117 0.4971 0.0029 0.6184 0.4876 0.0124 0.4220
γ5 -0.5007 0.0007 0.1038 -0.4930 0.0070 0.6187 -0.4956 0.0044 0.3495
γ6 -0.2912 0.0088 0.1805 -0.2820 0.0180 0.4304 -0.2977 0.0023 0.4091
γ7 -0.2009 0.0009 0.1367 -0.1994 0.0006 0.2994 -0.2156 0.0156 0.3610
γ8 -1.0017 0.0017 0.0938 -1.0109 0.0109 0.6967 -0.9941 0.0059 0.5047
γ9 0.2161 0.0161 0.2210 0.1684 0.0316 1.6137 0.2048 0.0048 1.1404
γ10 0.2066 0.0066 0.1922 0.3155 0.1155 3.2384 0.2077 0.0077 0.9585
γ11 -0.0916 0.0084 0.1820 -0.0866 0.0134 1.3041 -0.1261 0.0261 0.7578
γ12 0.1026 0.0026 0.1122 0.1029 0.0029 1.5037 0.1421 0.0421 0.4783
p = 19000 and n = 1000
γ2 0.1985 0.0015 0.1576 0.1938 0.0062 0.3690 0.1823 0.0177 0.4729
γ3 0.3107 0.0107 0.1906 0.2885 0.0115 0.2536 0.2783 0.0217 0.6575
γ4 0.4992 0.0008 0.1886 0.4998 0.0002 0.4273 0.4875 0.0105 0.7609
γ5 -0.5044 0.0044 0.1708 -0.4983 0.0017 0.2736 -0.4990 0.0010 0.3195
γ6 -0.3028 0.0028 0.1908 -0.2985 0.0015 0.3726 -0.2971 0.0029 0.6644
γ7 -0.2016 0.0016 0.1361 -0.1876 0.0124 0.3348 -0.1720 0.0280 0.7898
γ8 -1.0161 0.0161 0.2377 -0.9668 0.0332 0.4235 -1.0113 0.0113 0.6882
γ9 0.2108 0.0108 0.2666 0.2510 0.0510 0.7091 0.2033 0.0033 1.3412
γ10 0.1846 0.0154 0.3846 0.1906 0.0094 0.5432 0.1728 0.0272 1.4365
γ11 -0.1082 0.0082 0.4312 -0.1631 0.0631 1.0603 -0.0988 0.0012 0.7355
γ12 0.1137 0.0137 0.1642 0.1066 0.0066 0.3429 0.0887 0.0113 0.7772
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Figure 3.1: Simulation 2. Boxplots of Euclidean distances ‖γ̂−γ‖ based on 1000 sim-
ulations, when there is no censoring (left), 20% censoring (middle) and 40% censoring
(right) based on three different n and p combinations.
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Table 3.3: Analysis of the breast cancer data with censoring. Estimates (est) are ob-
tained from the two-stage model. Sample mean of estimates (mean), sample median
of estimates (median), sample standard deviation (std) and sample median absolute
deviation (mad) are calculated based on 1000 bootstrap samples. The pathway ac-
tivity level indices in the second stage survival model are γi, i = 2, · · · , 8, and γ9 is
the index corresponding to age.
γ2 γ3 γ4 γ5 γ6 γ7 γ8 γ9
est -2.4591 2.5606 1.9657 -2.1220 2.0584 1.8624 1.7060 0.0878
mean -2.5368 2.6165 1.9785 -2.1641 2.0389 1.8670 1.7519 0.0568
median -2.5151 2.5929 1.9345 -2.1199 1.9645 1.8133 1.7360 0.0312
std 0.8940 0.9278 0.7769 0.8572 0.7588 0.7975 0.7378 0.6246
mad 0.8305 0.8353 0.7752 0.8088 0.8069 0.8089 0.7627 0.7770
p-value 0.0045 0.0048 0.0109 0.0116 0.0072 0.0192 0.0176 0.9275
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Figure 3.2: Plot of the estimated cumulative hazard functions Λ̂ for four cancer
subtypes. Upper-left panel: Λ̂ as a function of t while the index β̂Tf+ α̂TW is fixed
at its sample mean. Other panels: Λ̂ as a function of βTf+αTW while t is fixed at
600 (upper-right), 1200 (lower-left) and 3000(lower-right).
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Figure 3.3: Contour plots of Λ̂ as a function of βTf + αTW and t for each cancer
subtype, which are Basal, Her2-enriched, Luminal B, and Luminal A as labeled.
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Figure 3.4: Heatmaps of loading matrix B with genes in the p53 signaling pathway
for each of the five cancer subtypes. Brighter colors indicate larger impact on the
pathway activity—the brighter the color, the greater impact of the pathway activity.
The right side-bars by each heatmaps represent the L2 norm square of each row in
the loading matrix.
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Table 3.4: Genes that receive high joint pathway activity levels among 62 genes in
p53 signaling pathway, corresponding to brighteest stripes in heatmap in Figure 3.4.
“location” stands for the specific location among 62 genes in Figure 3.4, and the “L2
norm” does for norm square in log-scale.
subtype Basal Her2-enriched Luminal B Luminal A Normal-like
THBS1 THBS1 CCND1 THBS1 THBS1
(24, 21.30) (24, 21.08) (11, 22.08) (24, 21.21) (24, 21.30)
PERP PERP THBS1 CCND1 PERP
(52, 20.62) (52, 20.16) (24, 21.17) (11, 20.60) (52, 20.63)
gene name IGFBP3 CCND1 SHISA5 PERP CCND1
(location, (43, 19.03) (11, 19.58) (46, 18.80) (52, 19.02) (11, 19.43)
L2 norm) CCND1 SHISA5 PERP SHISA5 SERPINE1
(11, 18.95) (46, 18.71) (52, 18.77) (46, 18.51) (26, 19.43)
CDK4 IGFBP3 MDM2 CCNG2 IGFBP3
(7, 18.31) (43, 18.45) (10, 18.26) (30, 18.32) (43, 18.24)
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Table 3.5: The average of overall strengths of all genes belonging to each signaling
pathway for each cancer subtype, and it is log-scaled.
pathway Basal Her2-enriched Luminal B Luminal A Normal-like
estrogen 20.53 20.23 20.27 19.65 19.39
MAPK 18.32 18.18 18.30 18.04 18.39
PI3K-Akt 20.84 21.56 21.38 21.58 22.20
p53 17.94 17.75 18.46 17.81 17.95
notch 19.61 18.73 18.44 18.64 18.91
Wnt 17.87 17.59 18.15 17.89 18.48
Cell cycle 18.81 18.56 18.92 17.91 17.27
Homologous 15.56 15.12 15.45 14.98 14.68
67
Bibliography
S. C. Ahn and A. R. Horenstein. Eigenvalue ratio test for the number of factors.
Econometrica, 81(3):1203–1227, 2013.
J. Bai and S. Ng. Determining the number of factors in approximate factor models.
Econometrica, 70(1):191–221, 2002.
P. J. Bickel, C. A. J. Klaassen, Y. Ritov, and J. A. Wellner. Efficient and Adaptive Es-
timation for Semiparametric Models. Johns Hopkins University Press, Baltimore,
1993.
Cancer CGoHFiB. Familial breast cancer: collaborative reanalysis of individual data
from 52 epidemiological studies including 58,209 women with breast cancer and
101,986 women without the disease. The Lancet, 358(9291):1389–1399, 2001.
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast
tumors. Nature, 490(7418):61, 2012.
C. M. Carvalho, J. Chang, J. E. Lucas, J. R. Nevins, Q. Wang, and M. West. High-
dimensional sparse factor modeling: applications in gene expression genomics.
Journal of the American Statistical Association, 103(484):1438–1456, 2008.
D. Cook. Regression Graphics: Ideas for Studying Regressions through Graphics.
Wiley, New York, 1998.
H. Cui, R. Li, and W. Zhong. Model-free feature screening for ultrahigh dimensional
discriminant analysis. Journal of the American Statistical Association, 110(510):
630–641, 2015.
C. DeSantis, J. Ma, L. Bryan, and A. Jemal. Breast cancer statistics, 2013. CA: A
Cancer Journal for Clinicians, 64(1):52–62, 2014.
68
T. Dottorini, G. Sole, L. Nunziangeli, F. Baldracchini, N. Senin, G. Mazzoleni,
C. Proietti, L. Balaci, and A. Crisanti. Serum ige reactivity profiling in an asthma
affected cohort. PLoS one, 6(8):e22319, 2011.
M. L. Eaton. Multivariate statistics: A vector space approach. WILEY, New York,
1983.
J. Fan, L. Xue, and J. Yao. Sufficient forecasting using factor models. Journal of
Econometrics, 2017.
R. A. Fisher. The use of multiple measurements in taxonomic problems. Annals of
eugenics, 7(2):179–188, 1936.
M. A. García-Campos, J. Espinal-Enríquez, and E. Hernández-Lemus. Pathway anal-
ysis: state of the art. Frontiers in physiology, 6, 2015.
T. S. Gardner, D. Di Bernardo, D. Lorenz, and J. J. Collins. Inferring genetic networks
and identifying compound mode of action via expression profiling. Science, 301
(5629):102–105, 2003.
F. R. Hampel. Contribution to the theory of robust estimation. Ph. D. Thesis,
University of California, Berkeley, 1968.
F. R. Hampel. The influence curve and its role in robust estimation. Journal of the
american statistical association, 69(346):383–393, 1974.
F. Jiang, Y. Ma, and Y. Wei. Sufficient direction factor model and its appication for
eQTL discovery. Under Review, 2017.
M. Kanehisa and S. Goto. KEGG: Kyoto Encyclopedia of Genes and Genomes.
Nucleic Acids Research, 28(1):27–30, 2000.
KEGG. Kyoto encyclopedia of genes and genomes, 1995. URL
http://www.genome.jp/kegg/.
O. Komori, S. Eguchi, and J. B. Copas. Generalized t-statistic for two-group classi-
fication. Biometrics, 71:404–416, 2015.
69
M. Lacroix, R.-A. Toillon, and G. Leclercq. p53 and breast cancer, an update.
Endocrine-related cancer, 13(2):293–325, 2006.
C. Lam, Q. Yao, et al. Factor modeling for high-dimensional time series: inference
for the number of factors. The Annals of Statistics, 40(2):694–726, 2012.
H. Lian. Most: detecting cancer differential gene expression. Biostatistics, 9(3):
411–418, 2008.
W. Luo and B. Li. Combining eigenvalues and variation of eigenvectors for order
determination. Biometrika, 103(4):875–887, 2016.
Y. Ma and X. Zhang. A validated information criterion to determine the structural
dimension in dimension reduction models. Biometrika, 102(2):409–420, 2015.
Y. Ma and L. Zhu. A review on dimension reduction. International Statistical Review,
81(1):134–150, 2013.
K. V. Mardia, J. T. Kent, and J. M. Bibby. Multivariate analysis. Academic press,
1980.
J. S. Parker, M. Mullins, M. C. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies,
C. Fauron, X. He, Z. Hu, et al. Supervised risk predictor of breast cancer based
on intrinsic subtypes. Journal of clinical oncology, 27(8):1160–1167, 2009.
K. Stemke-Hale, A. M. Gonzalez-Angulo, A. Lluch, R. M. Neve, W.-L. Kuo,
M. Davies, M. Carey, Z. Hu, Y. Guan, A. Sahin, et al. An integrative genomic
and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Cancer research, 68(15):6084–6091, 2008.
J. Q. Su and J. S. Liu. Linear combinations of multiple diagnostic markers. Journal
of the American Statistical Association, 88(424):1350–1355, 1993.
R. Tibshirani and T. Hastie. Outlier sums for differential gene expression analysis.
Biostatistics, 8(1):2–8, 2007.
A. Tsiatis. Semiparametric Theory and Missing Data. Springer, New York, 2006.
70
Y. Wang, J. G. Klijn, Y. Zhang, A. M. Sieuwerts, M. P. Look, F. Yang, D. Talantov,
M. Timmermans, M. E. Meijer-van Gelder, J. Yu, et al. Gene-expression profiles
to predict distant metastasis of lymph-node-negative primary breast cancer. The
Lancet, 365(9460):671–679, 2005.
J. Zhang, J. Baran, A. Cros, J. M. Guberman, S. Haider, J. Hsu, Y. Liang, E. Rivkin,
J. Wang, B. Whitty, et al. International cancer genome consortium data portal—a
one-stop shop for cancer genomics data. Database, 2011, 2011.
G. Zhao, Y. Ma, and W. Lu. On estimation of general index model for survival data.
Under Review, 2017.
71
Appendix A
Supplement to Chapter 2
A.1 Derivation of T and T ⊥ under no assumption
For the joint pdf,
f(x, y) = {q0(2pi)−p/2 exp(−xTx/2)}1−y{(1− q0)θ(x)}y,
logf(x, y) = (1− y)log{q0(2pi)−p/2 exp(−xTx/2)}+ ylog(1− q0) + ylog{θ(x)},
taking derivative of logf(x, y) with respect to any potential parameters in the sub-
model of θ(x), we obtain
T = {Y a(X) :
∫
a(x)θ(x)dx = 0}
= [Y a(X) : E{a(X) | Y = 1} = 0].
Consider
0 = E{bT(X, Y )Y a(X)}
=
1∑
y=0
∫
bT(x, y)ya(x)f(x, y)dx
=
∫
bT(x, 1)a(x)(1− q0)θ(x)dx
and
0 = E{b(X, Y )}
=
1∑
y=0
∫
b(x, y)f(x, y)dx
=
∫
{b(x, 0)q0(2pi)−p/2 exp(−xTx/2) + b(x, 1)(1− q0)θ(x)}dx.
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This leads to b(x, 1) = c, and 0 = q0(2pi)−p/2
∫ b(x, 0) exp(−xTx/2)dx + c(1 − q0),
hence
c = −(1− q0)−1q0(2pi)−p/2
∫
b(x, 0) exp(−xTx/2)dx.
This leads to
T ⊥ = [(1− Y )b(X)− Y {(1− q0)−1q0(2pi)−p/2
∫
b(x) exp(−xTx/2)dx} : ∀b(X)].
A.2 Influence function of β̂ under no assumption
Let µ∗ ≡ (1− q0)µ and write δ = n−1∑ni=1 xiyi − µ∗ = Op(n−1/2). Then
n1/2(β̂ − β) = n1/2
[
n−1
∑n
i=1 xiyi
{(n−1∑ni=1 xiyi)T(n−1∑ni=1 xiyi)}1/2 −
µ
(µTµ)1/2
]
= n1/2
[
µ∗ + δ
{(µ∗ + δ)T(µ∗ + δ)}1/2 −
µ∗
(µ∗Tµ∗)1/2
]
= n1/2
{
µ∗ + δ
(µ∗Tµ∗ + 2µ∗Tδ + δTδ)1/2
− µ
∗
(µ∗Tµ∗)1/2
}
= n1/2
[ µ∗ + δ
(µ∗Tµ∗)1/2{1 + 2(µ∗Tµ∗)−1µ∗Tδ +Op(n−1)}1/2
− µ
∗
(µ∗Tµ∗)1/2
]
= n1/2
[
(µ∗ + δ){1− (µ∗Tµ∗)−1µ∗Tδ −Op(n−1)}
(µ∗Tµ∗)1/2 −
µ∗
(µ∗Tµ∗)1/2
]
= n1/2
{
I− µ∗(µ∗Tµ∗)−1µ∗T
(µ∗Tµ∗)1/2
}
δ + op(1)
= n−1/2
n∑
i=1
{
I− µ∗(µ∗Tµ∗)−1µ∗T
(µ∗Tµ∗)1/2
}
(xiyi − µ∗) + op(1)
= n−1/2
n∑
i=1
{
I− µ(µTµ)−1µT
(1− q0)(µTµ)1/2
}
{xiyi − (1− q0)µ}+ op(1)
= n−1/2
n∑
i=1
I− µ(µTµ)−1µT
(1− q0)(µTµ)1/2 xiyi + op(1).
A.3 Derivation of Λ and Λ⊥ under linearity
For the joint pdf,
f(x, y) = {q0(2pi)−p/2 exp(−xTx/2)}1−y{(1− q0)θ1(βTx)θ2(x,βTx)}y,
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taking derivative of logf(x, y) with respect to any potential parameters in the sub-
model of θ1(βTx), θ2(x,βTx), we obtain the nuisance tangent space Λ = Λ1 + Λ2,
where
Λ1 = {Y a(βTX) :
∫
a(βTx)θ1(βTx)d(βTx) = 0}
= [Y a(βTX) : E{a(βTX) | Y = 1} = 0],
Λ2 = {Y a(X,βTX) :
∫
βTx fixed
a(x,βTx)θ2(x,βTx)dx = 0,∫
βTx fixed
xaT(x,βTx)θ2(x,βTx)dx = 0}
= [Y a(X,βTX) : E{a(X,βTx) | βTx, Y = 1} = 0,
E{XaT(X,βTx) | βTx, Y = 1} = 0]
= [Y a(X,βTX) : E{a(X,βTx) | βTx, Y = 1} = 0,
E{(X− ββTX)aT(X,βTx) | βTx, Y = 1} = 0].
It is easy to verify that Λ1 ⊥ Λ2, hence Λ = Λ1 ⊕ Λ2. Combining the results on Λ1
and Λ2, we can further write Λ as
Λ = [Y a(X,βTX) : E{a(X,βTX) | Y = 1} = 0,
E{(X− ββTX)aT(X,βTx) | βTx, Y = 1} = 0].
Consider b(x, y) so that for all Y a(X,βTX) ∈ Λ,
0 = E{bT(X, Y )Y a(X,βTX)}
=
1∑
y=0
∫
bT(x, y)ya(x,βTx)f(x, y)dx
=
∫
bT(x, 1)a(x,βTx)(1− q0)θ1(βTx)θ2(x,βTx)dx
and
0 = E{b(X, Y )}
=
1∑
y=0
∫
b(x, y)f(x, y)dx
=
∫
{b(x, 0)q0(2pi)−p/2 exp(−xTx/2) + b(x, 1)(1− q0)θ1(βTx)θ2(x,βTx)}dx.
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The first requirement leads to b(x, 1) = B1(βTx)(x − ββTx) + c. The second re-
quirement further leads to 0 = q0(2pi)−p/2
∫ b(x, 0) exp(−xTx/2)dx+c(1− q0), hence
c = −(1− q0)−1q0(2pi)−p/2
∫
b(x, 0) exp(−xTx/2)dx.
This leads to
Λ⊥ = [(1− Y )b0(X) + Y {B1(βTx)(x− ββTx)− q0/(1− q0)(2pi)−p/2 ×∫
b0(x) exp(−xTx/2)dx} : ∀b0(X),B1(βTx)].
A.4 Simplication of E[Y {B1(βTX)U1}⊗2]
We first inspect closely the integration
∫
βTx fixed θ
′
2(x,βTx)xxTdx. We define
X˜ ≡
X˜1
X˜2
 ≡
β
TX
ATX
 = BTX,
where B = (β A) is a p × p orthonormal matrix, i.e. BTB = BBT = Ip. Then we
have
∫
βTx fixed
θ′2(x,βTx)xxTdx =
∫
θ′2(Bx˜, x˜1)Bx˜x˜TBT|B|dx˜2
=
∫
θ˜′2(x˜2, x˜1)Bx˜x˜TBTdx˜2
= B
∫ ∂θ˜2(x˜2, x˜1)
∂x˜1
 x˜21 x˜1x˜
T
2
x˜2x˜1 x˜2x˜T2
 dx˜2BT,
where we use θ˜2(x˜2, x˜1) to denote the density function of x˜2 conditional on x˜1, and
θ˜′2(x˜2, x˜1) = ∂θ˜2(x˜2, x˜1)/∂x˜1. Let
M ≡
∫ ∂θ˜2(x˜2, x˜1)
∂x˜1
 x˜21 x˜1x˜
T
2
x˜2x˜1 x˜2x˜T2
 dx˜2.
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The four submatrices of M are therefore respectively
M11 = x˜21
∂
∂x˜1
∫
θ˜2(x˜2, x˜1)dx˜2 = 0
M12 = x˜1
∫ ∂θ˜2(x˜2, x˜1)
∂x˜1
x˜T2 dx˜2
= x˜1
∂
∂x˜1
∫
θ˜2(x˜2, x˜1)x˜T2 dx˜2
= x˜1
∂
∂x˜1
E(X˜2 | x˜1, Y = 1)
= x˜1
∂
∂x˜1
E(ATX | βTx, Y = 1)
= x˜1
∂
∂x˜1
ATββTx
= 0
M21 = 0
M22 =
∂
∂x˜1
∫
θ˜2(x˜2, x˜1)x˜2x˜T2 dx˜2
= ∂
∂x˜1
E(X˜2X˜
T
2 | x˜1, Y = 1)
= ∂A
TE(XXT | βTX = βTx, Y = 1)A
∂(βTx)
.
Hence we have
∫
βTx fixed
θ′2(x,βTx)xxTdx = BMBT
= (β A)
0 0
0 AT ∂TE(XX
T|βTX=βTx,Y=1)
∂(βTx) A

β
T
AT

=
(
0 (I− ββT)∂TE(XXT|βTX=βTx,Y=1)
∂(βTx) A
)β
T
AT

= (I− ββT)∂
TE(XXT | βTX = βTx, Y = 1)
∂(βTx)
×(I− ββT)
= Q∂E(XX
T | βTX = βTx, Y = 1)
∂(βTx)
Q, (A.1)
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where we let Q = I− ββT. Using the above results, we further simplify
E(U∗3UT1 | βTX = βTx, Y = 1)
= E
[{
θ′1(βTx)
θ1(βTx)
+ θ
′
2(X,βTx)
θ2(X,βTx)
}
XXTQ | βTX = βTx, Y = 1
]
= θ
′
1(βTx)
θ1(βTx)
E(XXT | βTX = βTx, Y = 1)Q+
(∫
βTx fixed
θ′2(x,βTx)xxTdx
)
Q
= θ
′
1(βTx)
θ1(βTx)
E(XXT | βTX = βTx, Y = 1)Q
+Q∂E(XX
T | βTX = βTx, Y = 1)
∂(βTx)
Q,
we have
B1(βTX) =
[
θ′1(βTX)
θ1(βTX)
E(XXT | βTX, Y = 1)Q+Q∂E(XX
T | βTX, Y = 1)
∂(βTX)
Q
]
×{E(U1UT1 | βTX, Y = 1)}−.
Assumption of var(X | βTX, Y = 1) = Q leads to E(U1UT1 | βTX, Y = 1) = Q
and B1(βTX) can be further simplified as
B1(βTX) =
[
θ′1(βTX)
θ1(βTX)
{Q+ (βTX)2ββT}Q +Q{2(βTX)ββT}Q
]
Q−
= θ
′
1(βTX)
θ1(βTX)
QQ−,
Hence, define κ ≡ E[{θ′1(βTX)/θ1(βTX)}2 | Y = 1], we obtain
E[Y {B1(βTX)U1}⊗2] = E{YB1(βTX)U1UT1BT1 (βTX)}
= E{YB1(βTX)QBT1 (βTX)}
= (1− q0)E
{θ′1(βTX)
θ1(βTX)
}2
| Y = 1
Q
= (1− q0)κQ.
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A.5 Derivation of Λ and Λ⊥ under both assumptions
Taking derivative of logf(x, y) with respect to any potential parameters in the
submodel of θ1(αTx), θ2(x,αTx), we obtain Λ = Λ1 + Λ2, where
Λ1 = {Y a(αTX) :
∫
a(αTx)θ1(αTx)d(αTx) = 0, a ∈ Rp−1}
= [Y a(αTX) : E{a(αTX) | Y = 1} = 0, a ∈ Rp−1],
Λ2 = {Y a(X,αTX) :
∫
αTx fixed
a(x,αTx)θ2(x,αTx)dx = 0,∫
αTx fixed
xaT(x,αTx)θ2(x,αTx)dx = 0,∫
αTx fixed
vec(xxT)aT(x,αTx)θ2(x,αTx)dx = 0, a ∈ Rp−1}
= [Y a(X,αTX) : E{a(X,αTx) | αTx, Y = 1} = 0,
E{XaT(X,αTx) | αTx, Y = 1} = 0,
E{vec(XXT)aT(X,αTx) | αTx, Y = 1} = 0]
= (Y a(X,αTX) : E{a(X,αTx) | αTx, Y = 1} = 0,
E[{X− (αTα)−1ααTX}aT(X,αTx) | αTx, Y = 1] = 0,
E[vec{XXT −Q− (αTα)−2(ααTX)⊗2}aT(X,αTx) | αTx, Y = 1,
a ∈ Rp−1] = 0).
It is easy to verify that Λ1 ⊥ Λ2, hence Λ = Λ1 ⊕ Λ2. Combining the results on Λ1
and Λ2, we can further write Λ as
Λ = (Y a(X,αTX) : E{a(X,αTX) | Y = 1} = 0,
E[{X− (αTα)−1ααTX}aT(X,αTx) | αTx, Y = 1] = 0,
E[vec{XXT −Q− (αTα)−2(ααTX)⊗2}aT(X,αTx) | αTx, Y = 1] = 0,
a ∈ Rp−1).
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Consider b(x, y) so that for all Y a(X,αTX) ∈ Λ,
0 = E{bT(X, Y )Y a(X,αTX)}
=
1∑
y=0
∫
bT(x, y)ya(x,αTx)f(x, y)dx
=
∫
bT(x, 1)a(x,αTx)(1− q0)θ1(αTx)θ2(x,αTx)dx
and
0 = E{b(X, Y )}
=
1∑
y=0
∫
b(x, y)f(x, y)dx
=
∫
{b(x, 0)q0(2pi)−p/2 exp(−xTx/2) + b(x, 1)(1− q0)θ1(αTx)θ2(x,αTx)}dx.
The first requirement leads to
b(x, 1) = B1(αTx){x− (αTα)−1ααTx}+B2(αTx)vec{xxT −Q−
(αTα)−2(ααTx)⊗2}+ c.
The second requirement further leads to
q0(2pi)−p/2
∫
b(x, 0) exp(−xTx/2)dx+ c(1− q0) = 0,
hence
c = −(1− q0)−1q0(2pi)−p/2
∫
b(x, 0) exp(−xTx/2)dx.
This leads to
Λ⊥ =
(
(1− Y )b0(X) + Y [B1(αTx){x− (αTα)−1ααTx}
+B2(αTx)vec{xxT −Q− (αTα)−2(ααTx)⊗2}
−q0/(1− q0)(2pi)−p/2
∫
b0(x) exp(−xTx/2)dx] :
∀b0(X) ∈ Rp−1,B1(αTx) ∈ R(p−1)×p,B2(αTx) ∈ R(p−1)×p2
)
.
79
A.6 Derivation of the influence function for β̂K
Komori’s estimator aims at maximizing LU(β) with respect to β, where m =
E(βTX) and σ2 = var(βTX) are the marginal mean and variance of βTX. Note that
m = E{E(βTX | Y )}
= E(βTX | Y = 1)(1− q0) + E(βTX | Y = 0)q0
= (1− q0)
∫
βTxθ˜1(βTx)dµ(βTx)
= (1− q0)
∫
tθ˜1(t)dµ(t),
and
σ2 = var{E(βTX | Y )}+ E{var(βTX | Y )}
= var{E(βTX | Y = 1)I(Y = 1) + E(βTX | Y = 0)I(Y = 0)}
+E{var(βTX | Y = 1)I(Y = 1) + var(βTX | Y = 0)I(Y = 0)}
= var{E(βTX | Y = 1)I(Y = 1)}+ E{var(βTX | Y = 1)I(Y = 1)}+ q0
= {E(βTX | Y = 1)}2q0(1− q0) + var(βTX | Y = 1)(1− q0) + q0
= {E(βTX | Y = 1)}2q0(1− q0) + E{(βTX)2 | Y = 1}(1− q0)
−{E(βTX | Y = 1)}2(1− q0) + q0
= E{(βTX)2 | Y = 1}(1− q0)− {E(βTX | Y = 1)}2(1− q0)2 + q0
=
∫
(βTx)2θ˜1(βTx)dµ(βTx)(1− q0)− {
∫
βTxθ˜1(βTx)dµ(βTx)}2(1− q0)2 + q0
=
∫
t2θ˜1(t)dµ(t)(1− q0)− {
∫
tθ˜1(t)dµ(t)}2(1− q0)2 + q0,
both are free of β. However, both m and σ2 depend on θ˜1, an unknown function.
Komori et al. (2015) thus replaces θ˜1(βTx) with a kernel estimator with bandwidth
h.
At a given θ˜1(·), maximizing LU(β) is equivalent to solving ∂LU(β)/∂β = 0,
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where
∂LU(β)
∂β
= 1
n1
n∑
j=1
U ′
{
βT(xj − x¯)
(βTSβ)1/2
}
[(βTSβ)−1/2(xj − x¯)− βT(xj − x¯)(βTSβ)−3/2Sβ]×
I(Yj = 1).
Note that x¯ p→ 0 and S p→ Ip as the rate of 1/√n0 as n0 →∞, hence the estimating
equation can be written as
0 = 1√
n
n∑
j=1
U ′
{
βT(xj − x¯)
(βTSβ)1/2
}{
xj − x¯
(βTSβ)1/2
− β
T(xj − x¯)Sβ
(βTSβ)3/2
}
I(Yj = 1)
= 1√
n
n∑
j=1
U ′(βTxj)(xj − βTxjβ)I(Yj = 1)
+ ∂
∂x¯T
 1√
n
n∑
j=1
U ′
{
βT(xj − x¯)
(βTSβ)1/2
}{
xj − x¯
(βTSβ)1/2
− β
T(xj − x¯)Sβ
(βTSβ)3/2
}
×I(Yj = 1)
∣∣∣∣∣∣
x¯=0
(x¯− 0)
+ ∂
∂(Sβ)T
 1√
n
n∑
j=1
U ′
{
βT(xj − x¯)
(βTSβ)1/2
}{
xj − x¯
(βTSβ)1/2
− β
T(xj − x¯)Sβ
(βTSβ)3/2
}
×I(Yj = 1)
∣∣∣∣∣∣
Sβ=β
(Sβ − β) +Op(n−1)
√
n.
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This further leads to
0 = 1√
n
n∑
j=1
U ′(βTxj)(xj − βTxjβ)I(Yj = 1)
+
[
1√
n
n∑
j=1
U ′′{βT(xj − x¯)}β{(xj − x¯)− βT(xj − x¯)β}TI(Yj = 1)
+ 1√
n
n∑
j=1
U ′{βT(xj − x¯)}(−Ip + ββT)I(Yj = 1)
]∣∣∣∣∣
x¯=0
(x¯− 0)
+
 1√
n
n∑
j=1
U ′′
{
βTxj
(βTSβ)1/2
}{
−12(β
TSβ)−3/2ββTxj
}{ xj
(βTSβ)1/2
− β
TxjSβ
(βTSβ)3/2
}T
I(Yj = 1) +
1√
n
n∑
j=1
U ′
{
βTxj
(βTSβ)1/2
}{
− 12(β
TSβ)−3/2βxTj
−βTxj(βTSβ)−3/2Ip + 32(β
TSβ)−5/2ββTxjβTS
}
×I(Yj = 1)
∣∣∣∣∣
Sβ=β
(Sβ − β) + op(1)
= 1√
n
n∑
j=1
U ′(βTxj)QxjI(Yj = 1)
+
 1√n
n∑
j=1
U ′′(βTxj)βxTj QI(Yj = 1)−
1√
n
n∑
j=1
U ′(βTxj)QI(Yj = 1)
 x¯
+
 1√
n
n∑
j=1
{
U ′′(βTxj)
(
−12ββ
Txj
)
(xj − βTxjβ)T + U ′(βTxj)
×
(
−12βx
T
j − βTxjIp +
3
2ββ
TxjβT
)}
I(Yj = 1)
(Sβ − β) + op(1)
= 1√
n
n∑
j=1
U ′(βTxj)QxjI(Yj = 1) (A.2)
+
 1√n
n∑
j=1
U ′′(βTxj)βxTj QI(Yj = 1)−
1√
n
n∑
j=1
U ′(βTxj)QI(Yj = 1)
 x¯
+
 1√
n
n∑
j=1
{
−12U
′′(βTxj)βTxjβxTj Q−
1
2U
′(βTxj)(βxTj + 2βTxjIp
−3βTxjββT)
}
I(Yj = 1)
(Sβ − β) + op(1)
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We can represent x¯ and S− Ip as follows.
x¯ = x¯− E(Xj | Yj = 0)
=
n−1
∑n
j=1 xjI(Yj = 0)
n−1
∑n
j=1 I(Yj = 0)
=
n−1
∑n
j=1 xjI(Yj = 0)
q0 + q0{n−1∑nj=1 I(Yj = 0)/q0 − 1}
= {n−1
n∑
j=1
q−10 xjI(Yj = 0)}[1− {n−1
n∑
j=1
I(Yj = 0)/q0 − 1}+Op(n−1)]
= {n−1
n∑
j=1
q−10 xjI(Yj = 0)} − {n−1
n∑
j=1
q−10 xjI(Yj = 0)}
×{n−1
n∑
j=1
I(Yj = 0)/q0 − 1}+Op(n−1)
= {n−1
n∑
j=1
q−10 xjI(Yj = 0)}+Op(n−1).
Also,
S− Ip =
n−1
∑n
j=1(xj − x¯)(xj − x¯)TI(Yj = 0)
n−1
∑n
j=1 I(Yj = 0)− n−1
− Ip
=
n−1
∑n
j=1{(xj − x¯)(xj − x¯)T − Ip}I(Yj = 0)
n−1
∑n
j=1 I(Yj = 0)
+Op(n−1)
=
n−1
∑n
j=1{(xj − x¯)(xj − x¯)T − Ip}I(Yj = 0)
q0[1 + {n−1∑nj=1 I(Yj = 0)/q0 − 1}] +Op(n−1)
= q−10 [n−1
n∑
j=1
{(xj − x¯)(xj − x¯)T − Ip}I(Yj = 0)]
×[1− {n−1
n∑
j=1
I(Yj = 0)/q0 − 1}+Op(n−1)] +Op(n−1)
= n−1
n∑
j=1
q−10 {(xj − x¯)(xj − x¯)T − Ip}I(Yj = 0) +Op(n−1)
= n−1
n∑
j=1
q−10 (xjxTj − x¯x¯T − Ip)I(Yj = 0) +Op(n−1)
= n−1
n∑
j=1
q−10 (xjxTj − Ip)I(Yj = 0) +Op(n−1).
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To investigate each term in (A.2), we have
n−1/2
n∑
j=1
U ′′(βTxj)βxTj QI(Yj = 1)x¯
= n−1/2
n∑
j=1
U ′′(βTxj)βxTj Q{n−1
n∑
i=1
q−10 xiI(Yi = 0) +Op(n−1)}I(Yj = 1)
= n−1/2
n∑
i=1
E{I(Yj = 1)U ′′(βTXj)βXTj }Qq−10 xiI(Yi = 0) + op(1),
n−1/2
n∑
j=1
U ′(βTxj)QI(Yj = 1)x¯
= n−1/2
n∑
j=1
U ′(βTxj)Q{n−1
n∑
i=1
q−10 xiI(Yi = 0) +Op(n−1)}I(Yj = 1)
= n−1/2
n∑
i=1
E{I(Yj = 1)U ′(βTXj)}Qq−10 xiI(Yi = 0) + op(1),
and
n−1/2
n∑
j=1
U ′′(βTxj)βTxjβxTj QI(Yj = 1)(S− Ip)β
= n−1/2
n∑
j=1
U ′′(βTxj)βTxjβxTj Q{n−1
n∑
i=1
q−10 (xixTi − Ip)I(Yi = 0) +Op(n−1)}
×I(Yj = 1)β
= n−1/2
n∑
i=1
E{I(Yj = 1)U ′′(βTXj)βTXjβXTj }Qq−10 (xixTi − Ip)I(Yi = 0)β + op(1),
n−1/2
n∑
j=1
U ′(βTxj)(βxTj + 2βTxjIp − 3βTxjββT)I(Yj = 1)(S− Ip)β
= n−1/2
n∑
j=1
U ′(βTxj)(βxTj + 2βTxjIp − 3βTxjββT)
×{n−1
n∑
i=1
q−10 (xixTi − Ip)I(Yi = 0) +Op(n−1)}I(Yj = 1)β
= n−1/2
n∑
i=1
E{I(Yj = 1)U ′(βTXj)(βXTj + 2βTXjIp − 3βTXjββT)}q−10 (xixTi − Ip)
×I(Yi = 0)β + op(1).
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Hence, the estimating equation continued from (A.2) is written as
0 = n−1/2
n∑
i=1
U ′(βTxi)QxiI(Yi = 1)
+n−1/2
[
n∑
i=1
E{I(Yj = 1)U ′′(βTXj)βXTj }Qq−10 xi
−
n∑
i=1
E{I(Yj = 1)U ′(βTXj)}Qq−10 xi
−12
n∑
i=1
E{I(Yj = 1)U ′′(βTXj)βTXjβXTj }Qq−10 (xixTi − Ip)β
−12
n∑
i=1
E{I(Yj = 1)U ′(βTXj)(βXTj + 2βTXjIp − 3βTXjββT)}
×q−10 (xixTi − Ip)β
]
I(Yi = 0) + op(1).
Now β̂ is the solution to the above estimating equation, hence we have
0 = n−1/2
n∑
i=1
(
U ′(β̂Txi)QxiI(Yi = 1) +
[
E{I(Yj = 1)U ′′(β̂TXj)β̂XTj }Qq−10 xi
−E{I(Yj = 1)U ′(β̂TXj)}Qq−10 xi −
1
2E{I(Yj = 1)U
′′(β̂TXj)β̂
TXjβ̂XTj }Q
×q−10 (xixTi − Ip)β̂ −
1
2E{I(Yj = 1)U
′(β̂TXj)(β̂XTj + 2β̂
TXjIp − 3β̂TXjβ̂β̂T
)}q−10 (xixTi − Ip)β̂
]
I(Yi = 0)
)
+ op(1)
= n−1/2
n∑
i=1
(
U ′(βTxi)QxiI(Yi = 1) +
[
E{I(Yj = 1)U ′′(βTXj)βXTj }Qq−10 xi
−E{I(Yj = 1)U ′(βTXj)}Qq−10 xi −
1
2E{I(Yj = 1)U
′′(βTXj)βTXjβXTj }Q
×q−10 (xixTi − Ip)β −
1
2E{I(Yj = 1)U
′(βTXj)(βXTj + 2βTXjIp − 3βTXjββT
)}q−10 (xixTi − Ip)β
]
I(Yi = 0)
)
+ n−1/2
n∑
i=1
(
U ′′(βTxi)QxixTi I(Yi = 1) +
∂
∂β
[
E{I(Yj = 1)U ′′(βTXj)βXTj }Qq−10 xi − E{I(Yj = 1)U ′(βTXj)}Qq−10 xi
−12E{I(Yj = 1)U
′′(βTXj)βTXjβXTj }Qq−10 (xixTi − Ip)β
−12E{I(Yj = 1)U
′(βTXj)(βXTj + 2βTXjIp − 3βTXjββT)}q−10 (xixTi − Ip)β
]
×I(Yi = 0)
)∣∣∣∣∣
β=β∗
(β̂ − β) + op(1),
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where β∗ is on the line connecting β̂ and β. From the above estimating equation, we
obtain[{
1
n
n∑
i=1
U ′′(βTxi)QxixTi I(Yi = 1) +
1
n
n∑
i=1
∂
∂β
RiI(Yi = 0)
}
+ op(1)
]√
n(β̂ − β)
= −n−1/2
n∑
i=1
{U ′(βTxi)QxiI(Yi = 1) +RiI(Yi = 0)}+ op(1),
where we let Ri ≡ [E{I(Yj = 1)U ′′(βTXj)βXTj }q−10 Qxi − E{I(Yj = 1)U ′(βTXj)}
q−10 Qxi−(1/2)E{I(Yj = 1)U ′′(βTXj)βTXjβXTj }q−10 Q(xixTi −Ip)β−(1/2)E{I(Yj =
1)U ′(βTXj)(βXTj + 2βTXjIp − 3βTXjββT)}q−10 (xixTi − Ip)β]I(Yi = 0). Note that
Ri has mean zero regardless of the β value, hence its derivative with respect to β
also has mean zero. Therefore,[
1
n
n1
n1
n∑
i=1
U ′′(βTxi)QxixTi I(Yi = 1) +
1
n
n∑
i=1
∂
∂β
RiI(Yi = 0)
]
= (1− q0)E{U ′′(βTX)QXXT | Y = 1}+ 0+ op(1)
= (1− q0)E[U ′′(βTX)QE{XXT | βTX, Y = 1} | Y = 1] + op(1)
= (1− q0)E{U ′′(βTX) | Y = 1}Q+ op(1)
≡ (1− q0)kQ+ op(1),
where we let k ≡ E{U ′′(βTX) | Y = 1}, and we have
{(1− q0)kQ+ op(1)}
√
n(β̂ − β) (A.3)
= −n−1/2
n∑
i=1
{U ′(βTxi)QxiI(Yi = 1) +RiI(Yi = 0)}+ op(1).
When the kernel estimator θ̂1(βTx) is used to replace θ˜1(βTx), if we still use the
same estimating equation, all the derivations above remain the same except that the
function U now depends on an estimated version of θ˜1(·), say θ̂1(·) and hence (A.3)
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becomes
{(1− q0)kQ+ op(1)}
√
n(β̂ − β)
= −n−1/2
n∑
i=1
{U ′(βTxi, θ̂1)QxiI(Yi = 1) +RiI(Yi = 0)}+ op(1)
= −n−1/2
n∑
i=1
(
[U ′(βTxi) +
∂U ′{βTxi, θ˜1}
∂θ˜1
(θ̂1 − θ˜1) +Op{h4 + (nh)−1}]
×QxiI(Yi = 1) +RiI(Yi = 0)) + op(1)
= −n−1/2
n∑
i=1
{
U ′(βTxi)QxiI(Yi = 1) +RiI(Yi = 0)
}
−n−1/2
n∑
i=1
∂
∂θ˜1
[
U ′{βTxi, θ˜1}QxiI(Yi = 1) +RiI(Yi = 0)
]
(θ̂1 − θ˜1) + op(1),
as long as nh2 → ∞ and nh8 → 0. Here the derivative with respect to the function
θ˜1(·) is the Fréchet derivative. Now note that
E
(
∂
∂θ˜1
[
U ′{βTxi, θ˜1}QxiI(Yi = 1) +RiI(Yi = 0)
])
= −E
([
U ′{βTxi, θ˜1}QxiI(Yi = 1) +RiI(Yi = 0)
] ∂f(x, y)
∂θ˜1
)
= 0
because [U ′{βTxi, θ˜1}QxiI(Yi = 1) +RiI(Yi = 0)] ∈ Λ⊥. Therefore, the second term
above is n−1/2∑ni=1 ∂ [U ′{βTxi, θ˜1}QxiI(Yi = 1) +RiI(Yi = 0)] /∂θ˜1(θ̂1 − θ˜1)
= Op(1)(θ̂1 − θ˜1) = op(1). Thus, using the estimated θ̂1, we still obtain (A.3). Define
ϕ(Xi, Yi) = −(1− q0)−1{U ′(βTxi)QxiI(Yi = 1) +RiI(Yi = 0)},
we then have
√
nkQ(β̂K − β) = n−1/2
n∑
i=1
ϕ(Xi, Yi) + op(1). (A.4)
We now convert the results regarding β̂ to α̂L. Since α = β/β1 and α̂ = β̂/β̂1,
the left side of (A.4) can be rewritten as
√
nkQ(β̂1α̂− β1α) =
√
nkQ{(β̂1 − β1)(α̂−α) + β1(α̂−α) + (β̂1 − β1)α}
=
√
nβ1kQ(α̂−α) +
√
nkQ(β̂1 − β1)α+ op(1)
=
√
nβ1kQ(α̂−α) + op(1),
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where Qα = 0. Hence, we have
√
nβ1kQ(α̂−α) = n−1/2
n∑
i=1
ϕ(Xi, Yi) + op(1).
For the partitioned matrix Q =
(
Q11 Q12
Q21 QLL
)
, it is easy to check Q21 = −QLLαL,
therefore Q−1LLQ21 = −αL since QLL is invertible. By premultiplying Q−1LL(0, Ip−1) to
both sides, we obtain
√
nβ1kQ−1LL(0, Ip−1)Q(α̂−α) = n−1/2
n∑
i=1
Q−1LL(0, Ip−1)ϕ(Xi, Yi) + op(1),
=⇒ √n(α̂L −αL) = n−1/2
n∑
i=1
1
β1k
Q−1LL(0, Ip−1)ϕ(Xi, Yi) + op(1).
Therefore the influence function of Komori et al. (2015) estimator is
ϕK(Xi, Yi) =
1
β1k
Q−1LL(0, Ip−1)ϕ(Xi, Yi)
= − 1(1− q0)β1kQ
−1
LL(0, Ip−1){U ′(βTxi)QxiI(Yi = 1) +RiI(Yi = 0)}
A.7 Proof of Proposition 2.1
An influence function should satisfy the following properties.
(i) ϕK ∈ Λ⊥
(ii) E(ϕKSTα) = Ip−1.
We first verify that (i) holds. Let
b0(X) ≡ {(1− q0)β1k}−1Q−1LL(0, Ip−1)
×[E{I(Yj = 1)U ′′(βTXj)βXTj }q−10 QX− E{I(Yj = 1)U ′(βTXj)}q−10 QX
−(1/2)E{I(Yj = 1)U ′′(βTXj)βTXjβXTj }q−10 Q(XXT − Ip)β
−(1/2)E{I(Yj = 1)U ′(βTXj)(βXTj + 2βTXjIp − 3βTXjββT)}
×q−10 (XXT − Ip)β],
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B1(αTx) ≡ −{(1− q0)β1k}−1U ′(βTx)Q−1LL(0, Ip−1) and B2(αTX) = 0. Then
∫
b0(x) exp(−xTx/2)dx = 0.
and
ϕK(X, Y ) = (1− Y )b0(X) + YB1(αTx){X− (αTα)−1ααTX},
hence ϕK(X, Y ) is a valid element form of Λ⊥.
We now verify that (ii) holds. We have
ϕKSTα = −{(1− q0)β1k}−1Q−1LL(0, Ip−1){U ′(βTX)QXI(Y = 1) +RI(Y = 0)}
×Y
{
θ′1(αTx)
θ1(αTx)
+ θ
′
2(x,αTx)
θ2(x,αTx)
}
XT(0, Ip−1)T
= −{(1− q0)β1k}−1Q−1LL(0, Ip−1){U ′(βTX)QX}Y
{
θ′1(αTx)
θ1(αTx)
+ θ
′
2(x,αTx)
θ2(x,αTx)
}
×XT(0, Ip−1)T
Let θ˜1(βTX) be the pdf of βTX. Since αTx = (1/β1)βTx and ∂(αTx) =
(1/β1)∂(βTx), we have
θ˜1(βTx) =
1
β1
θ1
(
1
β1
βTx
)
= 1
β1
θ1(αTx),
∂θ˜1(βTx)
∂(βTx)
= 1
β21
θ′1
(
1
β1
βTx
)
= 1
β21
θ′1(αTx),
θ˜′1(βTx)
θ˜1(βTx)
= (1/β
2
1)θ˜′1(αTx)
(1/β1)θ˜1(αTx)
= 1
β1
θ′1(αTx)
θ1(αTx)
.
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Noting above results, we have
E(ϕKSTα)
= −{(1− q0)β1k}−1Q−1LL(0, Ip−1)E
{
U ′(βTX)QXY
(
θ′1
θ1
+ θ
′
2
θ2
)
XT
}
(0, Ip−1)T
= −{(1− q0)β1k}−1Q−1LL(0, Ip−1)
×(1− q0)E
[
U ′(βTX)QE
{(
θ′1
θ1
+ θ
′
2
θ2
)
XXT | αTX, Y = 1
}
| Y = 1
]
(0, Ip−1)T
= −1/(β1k)Q−1LL(0, Ip−1)E[U ′(βTX)QE{(θ′1/θ1)XXT | αTX, Y = 1} | Y = 1]
×(0, Ip−1)T
= −1/(β1k)Q−1LL(0, Ip−1)E[U ′(βTX)Q(θ′1/θ1){Q+ (αTα)−2(ααTx)⊗2} | Y = 1]
×(0, Ip−1)T
= −1/(β1k)E
{
U ′(βTX)θ
′
1(αTX)
θ1(αTX)
| Y = 1
}
Ip−1
= [−β1E[{U ′′(βTX) | Y = 1]−1E
{
U ′(βTX)θ
′
1(αTX)
θ1(αTX)
| Y = 1
}
Ip−1
=
[
β1E
{
U ′(βTX) 1
β1
θ′1(αTX)
θ1(αTX)
| Y = 1
}]−1
E
{
U ′(βTX)θ
′
1(αTX)
θ1(αTX)
| Y = 1
}
Ip−1
= Ip−1.
Therefore, ϕK is a valid influence function in Λ⊥. In the above, the second last
equality is because
E{U ′′(βTX) | Y = 1} =
∫
U ′′(βTX)θ˜1(βTX)d(βTX)
= U ′(βTX)θ˜1(βTX)
∣∣∣∣∞−∞ −
∫
U ′(βTX)θ˜′1(βTX)d(βTX)
= −
∫
U ′(βTX)θ˜′1(βTX)β1d(αTX)
= −E
[
U ′(βTX) θ
′
1(αTX)
β1θ1(αTX)
| Y = 1
]
.
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A.8 Proof of Proposition 2.2
We first take a closer look at ϕKϕT3 using (2.8) and (2.10).
ϕKϕ
T
3 = −{(1− q0)β1k}−1Q−1LL(0, Ip−1){U ′(βTX)QXI(Y = 1) +RI(Y = 0)}
×Y {UT1BT1 (αTX) +UT2BT2 (αTX)}Vα,opt
= −{(1− q0)β1k}−1Q−1LL(0, Ip−1)U ′(βTX)QXY {UT1BT1 (αTX)
+UT2BT2 (αTX)}Vα,opt.
Thus, noting that E(U1UT1 | αTX, Y = 1) = QLL, E(U1UT2 | αTX, Y = 1) = 0, and
B1(αTX) = {θ′1(αTX)/θ1(αTX)}Ip−1, we obtain
E(ϕKϕT3 )
= −{(1− q0)β1k}−1Q−1LL(0, Ip−1)E{U ′(βTX)QXY {UT1BT1 (αTX) +UT2BT2 (αTX)}
×Vα,opt
= −{(1− q0)β1k}−1Q−1LL(0, Ip−1)E[U ′(βTX)QX{UT1BT1 (αTX)
+UT2BT2 (αTX)} | Y = 1](1− q0)Vα,opt
= −(β1k)−1Q−1LLE[{U ′(βTX)E(U1UT1 | αTX, Y = 1)BT1 (αTX)
+U ′(βTX)E(U1UT2 | αTX, Y = 1)BT2 (αTX)} | Y = 1]Vα,opt
= −(β1k)−1E{U ′(βTX)BT1 (αTX) | Y = 1}Vα,opt
= −(β1k)−1E
{
U ′(βTX)θ
′
1(αTX)
θ1(αTX)
| Y = 1
}
Vα,opt
= [−β1E[{U ′′(βTX)} | Y = 1]−1E
{
U ′(βTX)θ
′
1(αTX)
θ1(αTX)
| Y = 1
}
Vα,opt
=
[
β1E
{
U ′(βTX) 1
β1
θ′1(αTX)
θ1(αTX)
| Y = 1
}]−1
×E
{
U ′(βTX)θ
′
1(αTX)
θ1(αTX)
| Y = 1
}
Vα,opt
= Vα,opt
= E(ϕ3ϕT3 ),
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hence E{(ϕK − ϕ3)ϕT3 } = 0. Thus, we have var(ϕK) = var(ϕK − ϕ3) + var(ϕ3) +
E{(ϕK−ϕ3)ϕT3 }+E{ϕ3(ϕK−ϕ3)T} = var(ϕK−ϕ3)+var(ϕ3). Obviously ϕK 6= ϕ3,
hence the estimator by Komori et al. (2015) is indeed not efficient.
A.9 Proof of Corollary 2.1
From Su and Liu (1993), AUC can be represented as
AUC = E{F (Z)},
where F (·) is the distribution function of βTX of the control group, Z ∼ G(·) andG(·)
is the distribution function of βTX of the case group. Since βTX | Y = 0 ∼ N (0, 1),
viewing AUC as a function of the parameter β, AUC(β) = E{Φ(βTX)}, where Φ(·) is
the standard normal distribution function. We now show that AUC(β) is maximized
when β = β̂ among all possible estimators of β, which means our estimator β̂ achieves
the largest AUC among all possible estimators of β. Using a simple Taylor expansion
at the true parameter value, which we also denote β, we obtain
AUC(β̂) = AUC(β) + ∂AUC(β)
∂βT
(β̂ − β) + 12(β̂ − β)
T∂
2AUC(β)
∂β∂βT
(β̂ − β)
= AUC(β) + 12trace
{
∂2AUC(β)
∂β∂βT
(β̂ − β)(β̂ − β)T
}
+ op‖β̂ − β‖3
Here, the second summand is zero because AUC is maximized at the true β. Thus,
E{AUC(β̂)} = AUC(β) + 12trace
{
∂2AUC(β)
∂β∂βT
var(β̂ − β)
}
+ o(n−3/2).
Again, because AUC is maximized at the true β, ∂2AUC(β)/∂β∂βT is a negative
definite matrix. Because of the optimality of β̂, var(β̂ − β) is minimized. Thus, we
obtain
E{AUC(β̂)} > E{AUC(β˜)}
to the first leading order for any root-n consistent estimator β˜. This indicates that
β̂ has the optimality property in terms of AUC.
92
Appendix B
Supplement to Chapter 3
Regularity conditions and asymptotic results we describe in the Appendix are
based mainly on Section 3.3 in Zhao et al. (2017).
B.1 Assumptions
We describe some regularity conditions to be needed for asymptotics. Throughout
the Appendix, we let G be the parameter space of γ. The censoring process is defined
as Sc(z, f∗) = pr(C ≥ z|f∗), and the event process S(z,γTf∗) = pr(T ≥ z|γTf∗). We
let f(z,γTf∗) = −∂S(z,γTf∗)/∂z.
B1 The univariate kernel function K(x) is symmetric, monotonically decreasing
when x > 0 and differentiable, and has bounded derivative. Moreover,
∫
xjK(x)
dx = 0, for 1 ≤ j < ν, 0 < ∫ xνK(x)dx < ∞, ∫ K2(x)dx < ∞, ∫ x2K2(x)dx <
∞, ∫ K ′2(x)dx <∞, ∫ x2K ′2(x)dx <∞, ∫ K ′′2(x)dx <∞, ∫ x2K ′′2(x)dx <∞.
The d-dimensional kernel function is a product of d univariate kernel functions,
i.e., K(u) = Πdj=1K(uj) for u = (u1, · · · , ud)T. If it does not cause a confusion,
we use the same K for both univariate and multivariate kernel functions.
B2 h→ 0, b→ 0, nhd+2b→∞, and nh2ν → 0, where 2ν > d + 1, are satisfied for
the bandwidths.
B3 The parameter space G is bounded.
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B4 For all γ ∈ G, the probability density function of γTf∗, fγTf∗(γTf∗), has a
compact support and has four derivatives. The function fγTf∗(γTf∗) is bounded
away from zero and infinity on the support, and its first four derivatives are
bounded uniformly on the support.
B5 For all γ ∈ G, the absolute value of E{f∗jI(Yj ≥ Y )|γTf∗}, E{I(Yj ≥ Y )|γTf∗},
and their first four derivatives are component-wise uniformly bounded. The
absolute value of E{f∗j f∗jTI(Yj ≥ Y )|γTf∗} and its first two derivative are
component-wise uniformly bounded.
B6 For all γ ∈ G, the survival function of the event process S(t,γTf∗), the condi-
tional expectation of the survival function of the censoring processes E{Sc(t, f∗)|
γTf∗}, and the probability density function of the survival function f(t,γTf∗)
satisfy ∂i+jS(t,γTf∗)/∂ti∂(γTf∗)j, ∂i+jE{Sc(t, f∗)|γTf∗}/∂ti∂(γTf∗)j, ∂i+j
f(t,γTf∗)/∂ti∂(γTf∗)j exist and are bounded away from zero, for all i ≥ 0,
j ≥ 0, i+ j ≤ 4.
B7 The equation
E
(
∆λ1(Y,γ
Tf∗)
λ(Y,γTf∗) ⊗
[
f∗l −
E{f∗lU(Y )|γTf∗}
E{U(Y )|γTf∗}
])
= 0
has a unique solution on G. Because the only true γ0 satisfies the equation, the
unique solution is γ0.
B.2 Asymptotic resutls
Here we introduce some notations that are used in this subsection:
λ0(t,γT0 f∗) : the true hazard function,
λ10(t,γT0 f∗) ≡ ∂λ0(t,γT0 f∗)/∂(γT0 f∗),
N(t) ≡ ∆I(Y ≤ t),
M(t,γT0 f∗) ≡ N(t)−
∫ t
0
U(s)λ0(s,γT0 f∗)ds,
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then M(t,γT0 f∗) is mean-zero martingale process.
Now we provide the efficient score from Zhao et al. (2017) without detailed deriva-
tion process:
Seff(∆, Y, f∗) =
∫ ∞
0
λ10(s,γT0 f∗)
λ0(s,γT0 f∗)
⊗
[
f∗l −
E{f∗l Sc(s, f∗)|γT0 f∗}
E{Sc(s, f∗)|γT0 f∗}
]
dM(s,γT0 f∗).
Theorem 1. The estimator obtained from (3.4) is consistent, i.e. γ̂ − γ0 → 0 in
probability when n→∞.
Theorem 2. The estimator obtained from (3.4) satisfies
√
n(γ̂ − γ0)→ N (0, [E{S⊗2eff (∆, Y, f∗)}]−1)
in distribution when n→∞.
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B.3 Additional tables and plots
Table B.1: The list of 132 genes that are highly related to breast cancer.
132 genes in total
PIK3CA, PIK3CB, PTEN, AKT3, EGF, EGFR, ERBB2, AKT1, AKT2,
GSK3B, HRAS, IGF1, IGF1R, ARAF, KRAS, SHC4, NRAS, HEY2,
MAPK3, MAP2K1, MAP2K2, RPS6KB1, RPS6KB2, SHC1, SOS1, SOS2,
DLL3, JAG1, E2F1, E2F2, E2F3, ESR1, ESR2, FOS, DLL1, JAG2, JUN,
NOTCH2, NOTCH3, NOTCH4, DLL4, RB1, CCND1, NCOA3, BRCA1,
FGF5, FGF6, FGF7, FGF8, FGF9, FGF10, FGF11, FGF12, FGF13,
FGF21, FGF22, NFKB2, FGF23, FGF18, FGF17, FGF16, FGF19, FLT4,
PGR, FZD10, DVL2, DVL3, FZD2, LRP6, LRP5, WNT16, WNT4,
WNT5A, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT10B,
FZD1, FZD4, FZD6, FZD7, FZD8, FZD9, WNT3A, FRAT1, CSNK1A1L,
TCF7L2, AXIN1, AXIN2, TCF7L1, HES5, NCOA1, HEY1, HEYL,
CDKN1A, WNT9B, WNT10A, CDK4, FGF4, TNFSF11, LEF1, CDK6,
MTOR, SHC2, GRB2, PIK3R1, PIK3R2, SHC3, MAPK1, BRAF, PIK3R3,
NOTCH1, TCF7, BRCA2, FGF1, FGF3, FGF14, FGFR1, FGF20,
WNT1, WNT2, WNT3, WNT11, WNT2B, WNT9A, CSNK1A1, FRAT2,
WNT5B, KIT, CTNNB1
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Table B.2: Genes that receive high joint pathway activity levels among 87 genes in
estrogen signaling pathway, corresponding to brighteest stripes in heatmap in Figure
B.1. “location” stands for the specific location among 87 genes in Figure B.1, and
the “L2 norm” does for norm square in log-scale.
subtype Basal Her2 Luminal B Luminal A Normal
HSP90AB1 HSP90AA1 HSP90AB1 HSP90AB1 MMP2
(81, 23.64) (80, 23.20) (81, 23.31) (81, 22.52) (43, 22.02)
GNAS GNAS HSP90AA1 HSP90AA1 HSP90AB1
(41, 23.31) (41, 23.11) (80, 23.16) (80, 22.20) (81, 22.02)
gene name MMP9 HSP90AB1 GNAS HSPA8 GNAS
(location, (44, 23.14) (81, 23.05) (41, 22.85) (52, 22.14) (41, 21.74)
L2 norm) HSP90AA1 HSPA8 HSPA8 GNAS FOS
(80, 22.96 (52, 22.87) (52, 22.73) (41, 22.00) (40, 21.67)
HSPA8 HSP90B1 HSP90B1 HSPA1A HSP90AA1
(52, 22.66) (82, 21.78) (82, 21.91) (47, 21.49) (80, 21.55)
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Table B.3: Genes that receive high joint pathway activity levels among 234 genes in
MAPK signaling pathway, corresponding to brighteest stripes in heatmap in Figure
B.2. “location” stands for the specific location among 234 genes in Figure B.2, and
the “L2 norm” does for norm square in log-scale.
subtype Basal Her2 Luminal B Luminal A Normal
FLNA HSPA8 HSPA8 HSPA8 HSPB1
(103, 22.70) (58, 22.87) (58, 22.73) (58, 22.14) (118, 22.76)
HSPA8 FLNA HSPA1A FLNA FLNA
(58, 22.66) (103, 21.62) (53, 21.78) (103, 21.67) (103, 22.24)
gene name HSPA1A HSPA1A FLNB FLNB FOS
(location, (53, 21.26) (53, 21.52) (105, 21.75) (105, 21.50) (33, 21.67)
L2 norm) FLNB FLNB FLNA HSPA1A HSPA8
(105, 20.59) (105, 20.45) (103, 21.36) (53, 21.49) (58, 21.42)
STMN1 HSPB1 HSPB1 HSPB1 HSPA1A
(122, 20.34) (118, 20.28) (118, 21.17) (118, 20.30) (53, 20.69)
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Table B.4: Genes that receive high joint pathway activity levels among 321 genes
in PI3K-Akt signaling pathway, corresponding to brighteest stripes in heatmap in
Figure B.3. “location” stands for the specific location among 321 genes in Figure
B.3, and the “L2 norm” does for norm square in log-scale.
subtype Basal Her2 Luminal B Luminal A Normal
COL1A1 COL1A1 COL1A1 COL1A1 COL1A1
(261, 25.46) (261, 26.32) (261, 26.13) (261, 26.61) (261, 27.62)
FN1 FN1 FN1 COL1A2 COL1A2
(282, 25.29) (282, 26.20) (282, 25.95) (262, 26.04) (262, 26.44)
gene name COL1A2 COL1A2 COL1A2 FN1 FN1
(location, (262, 24.90) (262, 25.83) (262, 25.62) (282, 25.63) (282, 24.34)
L2 norm) HSP90AB1 HSP90AA1 HSP90AB1 COL6A3 COL6A3
(245, 23.64) (244, 23.20) (245, 23.31) (272, 23.10) (272, 23.45)
RPS6 COL6A3 HSP90AA1 RPS6 RPS6
(53, 23.27) (272, 23.06) (244, 23.16) (53, 22.68) (53, 23.14)
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Table B.5: Genes that receive high joint pathway activity levels among 47 genes in
notch signaling pathway, corresponding to brighteest stripes in heatmap in Figure
B.4. “location” stands for the specific location among 47 genes in Figure B.4, and
the “L2 norm” does for norm square in log-scale.
subtype Basal Her2 Luminal B Luminal A Normal
APP APP APP APP APP
(46, 23.29) (46, 22.33) (46, 21.85) (46, 22.18) (46, 22.57)
NOTCH3 NOTCH2 APH1A NOTCH2 NOTCH2
(10, 20.10) (9, 19.56) (34, 19.69) (9, 19.77) (9, 19.55)
gene name APH1A APH1A NOTCH2 APH1A NOTCH3
(location, (34, 20.01) (34, 19.25) (9, 19.49) (34, 19.43) (10, 19.35)
L2 norm) NOTCH2 NOTCH3 NCSTN NOTCH3 NCOR2
(9, 19.96) (10, 18.90) (30, 18.85) (10, 18.92) (44, 18.74)
NCSTN NCSTN NOTCH3 NCSTN APH1A
(30, 18.88) (30, 18.51) (10, 18.65) (30, 18.60) (34, 18.71)
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Table B.6: Genes that receive high joint pathway activity levels among 128 genes
in Wnt signaling pathway, corresponding to brighteest stripes in heatmap in Figure
B.5. “location” stands for the specific location among 128 genes in Figure B.5, and
the “L2 norm” does for norm square in log-scale.
subtype Basal Her2 Luminal B Luminal A Normal
SFRP1 SFRP2 CCND1 SFRP2 SFRP1
(108, 21.41) (109, 21.05) (15, 22.08) (109, 21.49) (108, 22.28)
CTNNB1 RHOA RHOA RHOA SFRP2
(34, 21.15) (33, 20.94) (33, 21.02) (33, 20.75) (109, 22.20)
gene name RHOA CTNNB1 SFRP2 CTNNB1 CTNNB1
(location, (33, 20.65) (34, 20.29) (109, 20.86) (34, 20.66) (34, 21.01)
L2 norm) MMP7 CSNK1A1 CTNNB1 CCND1 RHOA
(100, 20.22) (85, 19.77) (34, 20.54) (15, 20.60) (33, 20.23)
SFRP2 CCND1 CSNK1A1 CSNK1A1 JUN
(109, 19.70) (15, 19.58) (85, 20.13) (85, 19.94) (9, 20.07)
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Table B.7: Genes that receive high joint pathway activity levels among 112 genes
in cell cycle pathway, corresponding to brighteest stripes in heatmap in Figure B.6.
“location” stands for the specific location among 112 genes in Figure B.6, and the
“L2 norm” does for norm square in log-scale.
subtype Basal Her2 Luminal B Luminal A Normal
YWHAZ YWHAZ YWHAZ YWHAZ YWHAZ
(86, 22.82) (86, 22.61) (86, 22.75) (86, 21.36) (86, 20.58)
RAD21 YWHAE CCND1 YWHAE YWHAE
(72, 21.08) (83, 20.49) (12, 22.08) (83, 20.62) (83, 19.90)
gene name YWHAE RAD21 RAD21 CCND1 CCND1
(location, (83, 21.00) (72, 20.47) (72, 20.89) (12, 20.60) (12, 19.43)
L2 norm) PRKDC YWHAB YWHAE YWHAB YWHAB
(23, 20.75) (82, 20.46) (83, 20.78) (82, 19.99) (82, 19.30)
YWHAQ YWHAQ YWHAB SKP1 YWHAQ
(54, 20.59) (54, 20.33) (82, 20.66) (75, 19.67) (54, 19.15)
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Table B.8: Genes that receive high joint pathway activity levels among 32 genes in
homologous recombination pathway, corresponding to brighteest stripes in heatmap
in Figure B.7. “location” stands for the specific location among 32 genes in Figure
B.7, and the “L2 norm” does for norm square in log-scale.
subtype Basal Her2 Luminal B Luminal A Normal
SHFM1 POLD2 RAD50 RAD50 POLD2
(9, 17.66) (3, 17.20) (10, 17.36) (10, 16.96) (3, 16.74)
POLD2 SHFM1 POLD2 POLD2 ATM
(3, 17.60) (9, 17.00) (3, 17.30) (3, 16.71) (4, 16.39)
gene name SSBP1 RAD50 RBBP8 RBBP8 RAD50
(location, (8, 16.87) (10, 16.55) (21, 16.94) (21, 16.65) (10, 16.25)
L2 norm) TOPBP1 SSBP1 SHFM1 SHFM1 RBBP8
(11, 16.75) (8, 16.16) (9, 16.72) (9, 16.18) (21, 16.20)
RBBP8 TOPBP1 TOPBP1 ATM SHFM1
(21, 16.11) (11, 16.12) (11, 16.38) (4, 16.00) (9, 15.73)
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Figure B.1: Heatmaps of loading matrix B with genes in estrogen signaling pathway
for each of the five cancer subtypes. Brighter colors indicate larger impact on the
pathway activity—the brighter the color, the greater impact of the pathway activity.
The right side-bars by each heatmaps represent the L2 norm square of each row in
the loading matrix.
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Figure B.2: Heatmaps of loading matrix B with genes in MAPK signaling pathway
for each of the five cancer subtypes. Brighter colors indicate larger impact on the
pathway activity—the brighter the color, the greater impact of the pathway activity.
The right side-bars by each heatmaps represent the L2 norm square of each row in
the loading matrix.
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Figure B.3: Heatmaps of loading matrixB with genes in PI3K-Akt signaling pathway
for each of the five cancer subtypes. Brighter colors indicate larger impact on the
pathway activity—the brighter the color, the greater impact of the pathway activity.
The right side-bars by each heatmaps represent the L2 norm square of each row in
the loading matrix.
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Figure B.4: Heatmaps of loading matrix B with genes in notch signaling pathway
for each of the five cancer subtypes. Brighter colors indicate larger impact on the
pathway activity—the brighter the color, the greater impact of the pathway activity.
The right side-bars by each heatmaps represent the L2 norm square of each row in
the loading matrix.
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Figure B.5: Heatmaps of loading matrix B with genes in Wnt signaling pathway
for each of the five cancer subtypes. Brighter colors indicate larger impact on the
pathway activity—the brighter the color, the greater impact of the pathway activity.
The right side-bars by each heatmaps represent the L2 norm square of each row in
the loading matrix.
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Figure B.6: Heatmaps of loading matrix B with genes in cell cycle pathway for each
of the five cancer subtypes. Brighter colors indicate larger impact on the pathway
activity—the brighter the color, the greater impact of the pathway activity. The right
side-bars by each heatmaps represent the L2 norm square of each row in the loading
matrix.
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Figure B.7: Heatmaps of loading matrix B with genes in homologous recombination
pathway for each of the five cancer subtypes. Brighter colors indicate larger impact
on the pathway activity—the brighter the color, the greater impact of the pathway
activity. The right side-bars by each heatmaps represent the L2 norm square of each
row in the loading matrix.
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